US20010016604A1 - Additives enhancing topical actions of therapeutic agents - Google Patents

Additives enhancing topical actions of therapeutic agents Download PDF

Info

Publication number
US20010016604A1
US20010016604A1 US09774882 US77488201A US2001016604A1 US 20010016604 A1 US20010016604 A1 US 20010016604A1 US 09774882 US09774882 US 09774882 US 77488201 A US77488201 A US 77488201A US 2001016604 A1 US2001016604 A1 US 2001016604A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
acid
hydroxy
skin
pyruvate
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09774882
Inventor
Ruey Yu
Eugene Van Scott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tristrata Technology Inc
Tristrata Inc
Original Assignee
Yu Ruey J.
Van Scott Eugene J.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005Antimicrobial preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/191Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-arylpropionic acids, ethacrynic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/194Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • A61K8/347Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/362Polycarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365Hydroxycarboxylic acids; Ketocarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37Esters of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37Esters of carboxylic acids
    • A61K8/375Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/38Percompounds, e.g. peracids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42Amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/43Guanidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/60Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/63Steroids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • A61K8/671Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • A61K8/673Vitamin B group
    • A61K8/675Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • A61K8/676Ascorbic acid, i.e. vitamin C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/007Preparations for dry skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/008Preparations for oily skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/02Preparations for care of the skin for chemically bleaching or whitening the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/10Washing or bathing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/006Antidandruff preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/02Preparations for cleaning the hair
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q7/00Preparations for affecting hair growth
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/946Penetrant or absorbent, increases or enhances penetration into subject treated
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/946Penetrant or absorbent, increases or enhances penetration into subject treated
    • Y10S514/947Topical application

Abstract

Composition and method for enhancing therapeutic effects of topically applied agents are disclosed. The cosmetic or therapeutic composition may include one or more of cosmetic or pharmaceutical agents present in a total amount of from 0.01 to 40 percent and one or more of hydroxycarboxylic acids or related compounds present in a total amount of from 0.01 to 99 percent by weight of the total composition. The cosmetic and pharmaceutical agents may include but not limited to age spots, wrinkles and keratoses removing agents; vitamins; aloes; sun screens; tanning, depigmenting and shampooing agents; antiyeasts; antifungal, antibacterial and antiviral agents; topical bronchial dilators and topical cardiovascular agents; hormonal agents; vasodilators; retinoids and other dermatological agents. The hydroxycarboxylic acids and related compounds include organic alpha and beta hydroxycarboxylic acids, alpha and beta ketocarboxylic acids and salts thereof. Topical application of the cosmetic or therapeutic composition has been found to achieve a substantial increase in cosmetic or therapeutic effect of the active ingredient in humans and domesticated animals.

Description

  • This invention relates generally to method and composition containing hydroxyacid or related compound for enhancing therapeutic effects of cosmetic or pharmaceutical agent. As will be subsequently described in detail, we initially discovered that alpha hydroxy or keto acids and their derivatives were effective in the topical treatment of disease conditions such as dry skin, ichthyosis, eczema, palmar and plantar hyperkeratoses, dandruff, acne and warts. [0001]
  • We have now discovered that hydroxyacids or related compounds wherein incorporated into a therapeutic composition can substantially enhance topical effects of cosmetic and pharmaceutical agents. [0002]
  • In our prior U.S. Pat. No. 3,879,537 entitled “Treatment of Ichthyosiform Dermatoes” we described and claimed the use of certain alpha hydroxy acids, alpha keto acids and related compounds for topical treatment of fish-scale like ichthyotic conditions in humans. In our U.S. Pat. No. 3,920,835 entitled “Treatment of Disturbed Keratinization” we described and claimed the use of these certain alpha hydroxy acids, alpha keto acids and their derivatives for topical treatment of dandruff, acne, and palmar and plantar hyperkeratosis. [0003]
  • In our prior U.S. Pat. No. 4,105,783 entitled “Treatment of Dry Skin: we described and claimed the use of alpha hydroxy acids, alpha keto acids and their derivatives for topical treatment of dry skin. In our recent U.S. Pat. No. 4,246,261 entitled “Additives Enhancing Topical Corticosteroid Action” we described and claimed that alpha hydroxy acids, alpha keto acids and their derivatives, in small amounts could greatly enhance the therapeutic efficacy of corticosteroids in topical treatment of psoriasis, eczema, seborrheic dermatitis and other inflammatory skin conditions. [0004]
  • In our more recent U.S. Pat. No. 4,363,815 entitled “Alpha Hydroxy acids, Alpha Keto acids and Their Use in Treating Skin Conditions: we described and claimed that alpha hydroxy acids and alpha keto acids related to or originating from amino acids, whether or not found in proteins, were effective in topical treatment of skin disorders associated with disturbed keratinization or inflammation. These skin disorders include dry skin, ichthyosis, palmar and plantar hyperkeratosis, dandruff, Darier's disease, lichen simplex chronicus, keratoses, acne, psoriasis, eczema, pruritus and possibly warts and herpes. [0005]
  • In our most recent U.S. Pat. No. 4,518,789 entitled “Phenyl Alpha-Acyloxyacetamide Derivatives and Their Therapeutic Use” we described and claimed that phenyl alpha acyloxyacetamide derivatives in topical or systemic administration were useful and effective for pruritus, atopic dermatitis, eczema, psoriasis, acne, dry skin, dandruff, malodors of integumental areas, various aches, pains and discomforts of skin, joints and other body parts in humans and domestic animals. [0006]
  • The intact skin of humans is a very effective barrier to many natural and synthetic substances. Cosmetic and pharmaceutical agents may be pharmacologically effective by systemic administration, but many of them are much less or totally ineffective on topical application to the skin. Topical effectiveness of a pharmaceutical agent depends on two major factors a) Percutaneous absorption and penetration b) Bioavailability of the penetrated pharmaceutical agent to the target site in the skin. To be therapeutically effective as a topical agent a pharmaceutical drug must penetrate the stratum corneum into the epidermal layers, distributed and bioavailable to the target sites for pharmacologic action. Many pharmacologic agents can readily penetrate the skin but they are not bioavailable to the target sites in the skin, therefore therapeutic effect is minimal and ineffective. [0007]
  • It has now been discovered that hydroxyacids and related compounds including those described or not described in our previous patents and additional compounds can substantially enhance the therapeutic efficacy of cosmetic and pharmaceutical agents in topical treatment of cosmetic conditions, dermatologic disorders or other afflictions. Cosmetic and pharmaceutical agents may include any chemical substances natural or synthetic, intended for topical application to the skin or its appendages in human and animals. Some examples of cosmetic and pharmaceutical agents include age spots and keratoses removing agents, analgesics, anesthetics, antiacne agents, antibacterials, antiyeast agents, antifungal agents, antiviral agents, antiburn agents, antidandruff agents, antidermatitis agents, antipruritic agents, antiperspirants, antiinflammatory agents, antihyperkeratolytic agents, antidryskin agents, antipsoriatic agents, antiseborrheic agents, astringents, softeners, emollient agents, coal tar, bath oils, sulfur, rinse conditioners, foot care agents, fungicides, hair growth promoters, hair removers, keratolytic agents, moisturizer agents, powder, shampoos, skin bleaches, skin protectants, soaps, cleansers, antiaging agents, sunscreen agents, wart removers, wet dressings, vitamins, tanning agents, topical antihistamin agents, hormones, vasodilators, retinoids, bronchial dilators, topical cardiovascular agents and other dermatologicals. [0008]
  • The enhancing compounds of the instant invention are hydroxycarboxylic acids and related compounds. There are three groups of such hydroxyacids. The first is hydroxymonocarboxylic acids having the following chemical structure: [0009]
  • R1(CR2OH)m(CH2)nCOOH
  • wherein [0010]
  • R[0011] 1, R2=H, alkyl, aralkyl or aryl group of saturated or unsaturated, straight or branched chain or cyclic form, having 1 to 25 carbon atoms.
  • m=1, 2, 3, 4, 5, 6, 7, 8 or 9 [0012]
  • n=0 or a numerical number up to 23 [0013]
  • When n=0 and m=1 or more, the hydroxymonocarboxylic acid is also called aldonic acid. The name comes from a carbohydrate, aldose, which may be oxidized to aldonic acid by the oxidation of the aldehyde group in aldose to the carboyxlic group. [0014]
  • The hydroxymonocarboxylic acid may be present as a free acid, lactone, or salt form. The lactone form could be either inter or intramolecular lactone, however, most common ones are intramolecular lactones with a ring structure formed by elimination of one or more water molecules between a hydroxy group and the carboxylic group. Since the hydroxymonocarboxylic acids are organic in nature, they may form a salt or a complex with an inorganic or organic base such as ammonium hydroxide, sodium or potassium hydroxide, or triethanolamine. [0015]
  • The hydroxymonocarboxylic acid and its related compounds may also exist as stereoisomers such as D, L, and DL forms. [0016]
  • The typical alkyl, aralkyl and aryl groups for R[0017] 1 and R2 include methyl, ethyl, propyl, isopropyl, benzyl and phenyl. The hydrogen atoms of the R1 and R2 and (CH2)n may be substituted by a nonfunctional element such as F, Cl, Br, I, S or a radical such as a lower alkyl or alkoxy, saturated or unsaturated, having 1 to 9 carbon atoms. Representative hydroxymonocarboxylic acids are listed below:
  • 1. 2-Hydroxyacetic acid (Glycolic acid) [0018]
  • R[0019] 1=H, R2=H, m=1, n=0
  • 2. 2-Hydroxypropanoic acid (Lactic acid) [0020]
  • R[0021] 1=CH3, R2=H, m=1, n=0
  • 3. 2-Methyl 2-hydroxypropanoic acid (Methyllactic acid) [0022]
  • R[0023] 1=CH3, R2=CH3, m=1, n=0
  • 4. 2-Hydroxybutanoic acid [0024]
  • R[0025] 1=C2H5, R2=H, m=1, n=0
  • 5. Phenyl 2-hydroxyacetic acid (Mandelic acid) [0026]
  • R[0027] 1=C6H5, R2=H, m=1, n=0
  • 6. Phenyl 2-methyl 2-hydroxyacetic acid (Atrolactic acid) [0028]
  • R[0029] 1=C6H5, R2=CH3, m=1, n=0
  • 7. 3-Phenyl 2-hydroxypropanoic acid (Phenyllactic acid) [0030]
  • R[0031] 1=C6H5, R2=H, m=1, n=1
  • 8. 2,3-Dihydroxypropanoic acid (Glyceric acid) [0032]
  • R[0033] 1=H, R2=H, m=2, n=0
  • 9. 2,3,4-Trihydroxybutanoic acid [0034]
  • R[0035] 1=H, R2=H, m=3, n=0
  • 10. 2,3,4,5-Tetrahydroxypentanoic acid [0036]
  • R[0037] 1=H, R2=H, m=4, n=0
  • 11. 2,3,4,5,6-Pentahydroxyhenxanoic acid [0038]
  • R[0039] 1=H, R2=H, m=5, n=0
  • 12. 2-Hydroxydodecanoic acid (alpha hydroxylauric acid) [0040]
  • R[0041] 1=C10H21, R2=H, m=1, n=0
  • 13. 2,3,4,5,6,7-Hexahydroxyheptanoic acid [0042]
  • R[0043] 1=H, R2=H, m=6, n=0
  • 14. Diphenyl 2-hydroxyacetic acid (benzilic acid) [0044]
  • R[0045] 1=C6H5, R2=C6H5, m=1, n=0
  • 15. 4-Hydroxymandelic acid [0046]
  • R[0047] 1=C6H4(OH), R2=H, m=1, n=0
  • 16. 4-Chloromandelic acid [0048]
  • R[0049] 1=C6H4 (Cl), R2=H, m=1, n=0
  • 17. 3-Hydroxybutanoic acid [0050]
  • R[0051] 1=CH3, R2=H, m=1, n=1
  • 18. 4-Hydroxybutanoic acid [0052]
  • R[0053] 1=H, R2=H, m=a, n=2
  • 19. 2-Hydroxyhexanoic acid [0054]
  • R[0055] 1=C4H9, R2=H, m=1, n=0
  • 20. 5-Hydroxydodecanoic acid [0056]
  • R[0057] 1=C7H15, R2=H, m=1, n=3
  • 21. 12-Hydroxydodecanoic acid [0058]
  • R[0059] 1=H, R2=H, m=1, n=10
  • 22. 10-Hydroxydecanoic acid [0060]
  • R[0061] 1=H, R2=H, m=1, n=8
  • 23. 16-Hydroxyhexadecanoic acid [0062]
  • R[0063] 1=H, R2=H, m=1, n=14
  • 24. 2-Hydroxy-3-methylbutanoic acid [0064]
  • R[0065] 1=C3H7, R2=H, m=1, n=0
  • 25. 2-Hydroxy-4-methylpentanoic acid [0066]
  • R[0067] 1=C4H9, R2=H, m=1, n=0
  • 26. 3-Hydroxy-4-methoxymandelic acid [0068]
  • R[0069] 1=C6H3 (OH) (OCH3), R2=H, m=1, n=0
  • 27. 4-Hydroxy-3-methoxymandelic acid [0070]
  • R[0071] 1=C6H3 (OH) (OCH3), R2=H, m=1, n=0
  • 28. 2-Hydroxy-2-methylbutanoic acid [0072]
  • R[0073] 1=C2H5, R2=CH3, m=1, n=0
  • 29. 3-(2-Hydroxyphenyl) lactic acid [0074]
  • R[0075] 1=C6H4(OH) CH2, R2=H, m=1, n=0
  • 30. 3-(4-Hydroxyphenyl) lactic acid [0076]
  • R[0077] 1=C6H4 (OH) CH2, R2=H, m=1, n=0
  • 31. Hexahydromandelic acid [0078]
  • R[0079] 1=C6H11, R2=H, m=1, n=0
  • 32. 3-Hydroxy-3-methylpentanoic acid [0080]
  • R[0081] 1=C2H5, R2=CH3, m=1, n=1
  • 33. 4-Hydroxydecanoic acid [0082]
  • R[0083] 1=C6H13, R2=H, m=1, n=2
  • 34. 5-Hydroxydecanoic acid [0084]
  • R[0085] 1=C5H11, R2=H, m=1, n=3
  • 35. Aleuritic acid [0086]
  • R[0087] 1=C6H12(OH), R2=H, m=2, n=7
  • The linear lactic acid polymer is an intermolecular lactone formed by elimination of one water molecule between the hydroxy group of one molecule of lactic acid and the carboxylic group of a second molecule of lactic acid. The common linear lactic acid polymer may contain 3 lactic acid units. [0088]
  • Ribonic acid is one of the stereoisomers of 2,3,4,5-tetrahydroxypentanoic acid, and the corresponding lactone is ribonolactone. Gluconic acid, galactonic acid, gulonic acid and mannonic acid are typical 2,3,4,5,6-pentahydroxyhexanoic acids and their corresponding lactones are gluconolactone, galactonolactone, gulonolactone and mannonolactone respectively. The related compounds of hydroxymonocarboxylic acids are ketomonocarboxylic acids which are formed from the former by a oxidation reaction or in vivo by a dehydrogenase enzyme. For example, 2-ketopropanoic acid (pyruvic acid) and 2-hydroxypropanoic acid (lactic acid) are converted to each other in vivo by the enzyme, lactate dehydrogenase. Although pure pyruvic acid (liquid form) can be kept in a refrigerator for an extended period of time a composition containing pyruvic acid for topical use is not very stable at an elevated temperature. Therefore, for practical purposes pyruvic acid esters are used instead. [0089]
  • The representative esters are methyl pyruvate, ethyl pyruvate, propyl pyruvate and isopropyl pyruvate. Other representative ketomonocarboxylic acids and their esters are phenyl pyruvic acid and its esters such as methyl phenyl pyruvate, ethyl phenyl pyruvate and propyl phenyl pyruvate; formyl formic acid (2-ketoacetic acid) and its esters such as methyl, ethyl and propyl formyl formate; benzoyl formic acid and its esters such as methyl, ethyl and propyl benzoyl formate; 4-hydroxybenzoylformic acid and its esters; 4-hydroxyphenylpyruvic acid and its esters; 2-hydroxyphenylpyruvic acid and its esters. [0090]
  • Many hydroxy or ketomonocarboxylic acids are structurally related to amino acids either naturally occurring in proteins or not. For example alanine and pyruvic acid are interconverted to each other in vivo by an enzyme alanine dehydrogenase or alanine ketoglutarate transaminase. As mentioned earlier pyruvic acid and lactic acid are interconverted to each other in vivo by the enzyme lactate dehydrogenase. Therefore, alanine, pyruvic acid and lactic acid are chemically related in that the amino group of alanine may be converted to the keto group of pyruvic acid or the hydroxy group of lactic acid. The same relationships may apply to formyl formic acid and glycolic acid to glycine; hydroxpyruvic acid and glyceric acid to serine, phenyl pyruvic acid and phenyl lactic acid to phenylalanine; 2-keto- and 2-hydroxy-4 (methylthio) butanoic acids to methionine. [0091]
  • The second kind of hydroxyacid is hydroxydicarboxylic acid having the following chemical structure: [0092]
    Figure US20010016604A1-20010823-C00001
  • wherein [0093]
  • m=1, 2, 3, 4, 5, 6, 7, 8 or 9 [0094]
  • n=0 or a numerical number up to 23 [0095]
  • The hydroxydicarboxylic acid may also be present as a free acid, lactone or salt form. The lactone form could be either inter or intramolecular lactone. However, the common lactone is an intramolecular lactone with a ring structure formed by elimination of one or more water molecule between a hydroxy group and one of the carboxylic groups. Since the hydroxydicarboxylic acid is organic in nature, it may form a salt or a complex with an inorganic or organic base such as ammonium hydroxide. sodium or potassium hydroxide, or triethanolamine. [0096]
  • The hydroxydicarboxylic acid and its related compounds may also exist as stereoisomers such as D, L, DL and meso forms. [0097]
  • The hydrogen atom attached to the carbon atom may be substituted by a nonfunctional element such as F, Cl, Br, I, S or a radical such as a lower alkyl or alkoxy of saturated or unsaturated, having 1 to 9 carbon atoms. [0098]
  • When n=0 and m=1 or more, the hydroxydicarboxylic acid is also called aldaric acid. The name comes from the carbohydrate, and the common ones are saccharic acid and galactaric acid. Representative hydroxydicarboxylic acids are listed below: [0099]
  • 1. 2-Hydroxypropanedioic acid (Tartronic acid) [0100]
  • m=1, n=0 [0101]
  • 2. 2-Hydroxybutanedioic acid (Malic acid) [0102]
  • m=1, n=1 [0103]
  • 3. Erythraric acid and Threaric acid (Tartaric acid) [0104]
  • m=2, n=0 [0105]
  • 4. Arabiraric acid, Ribaric acid, Xylaric acid and Lyxaric acid [0106]
  • m=3, n=0 [0107]
  • 5. Glucaric acid (saccharic acid), Galactaric acid (Mucic acid), Mannaric acid, Gularic acid, Allaric acid, Altraric acid, Idaric acid and Talaric acid [0108]
  • m=4, n=0 [0109]
  • Commercially available saccharolactone (D-saccharic acid 1, 4-lactone) is an intramolecular lactone formed by elimination of one water molecule between the hydroxy group at position 4 and the carboxylic group at position 1. [0110]
  • The third type of hydroxyacid is a miscellaneous group of compounds which is not readily represented by the above generic structure. of either the first type or the second type. Included in the third type of hydroxyacids are the following: [0111]
  • Hydroxycarboxylic acid of [0112]
  • R(OH)m(COOH)n
  • Wherein m,n=1,2,3,4,5,6,7,8,or 9 [0113]
  • R=H, alkyl, aralkyl or aryl group of saturated or unsaturated, straight or branched chain or cyclic form, having 1 to 25 carbon atoms. [0114]
  • citric acid, isocitric acid, citramalic acid, agaricic acid (n-hexadecylcitric acid), quinic acid, uronic acids including glucuronic acid, glucuronolactone, galacturonic acid, galacturonolactone, hydroxypyruvic acid, hydroxypyruvic acid phosphate, ascorbic acid, dihydroascorbic acid, dihydroxytartaric acid, 2-hydroxy-2-methylbutanoic acid, 1-hydroxy-1-cyclopropane carboxylic acid, 2-hydroxyhexanedial, 5-hydroxylysine, 3-hydroxy-2-aminopentanoic acid, tropic acid, 4-hydroxy-2, 2-diphenylbutanoic acid, 3-hydroxy-3-methylglutaric acid, and 4-hydroxy-3-pentenoic acid. [0115]
  • The third type of hydroxyacid may also be present as a free acid, lactone or salt form. The lactone form could be either an inter or intramolecular lactone, however, most common are intramolecular lactones with a ring structure. Commonly known glucuronolactone is a r-lactone i.e. 1,4-lactone of intramolecular type. [0116]
  • The hydroxyacid of the third type may also exist as stereoisomers such as D, L, DL and meso forms. The hydrogen atom attached to the carbon atom may be substituted by a nonfunctional element such as F, Cl, Br, I, S or a radical such as a lower alkyl or alkoxy of saturated or unsaturated, having 1 to 9 carbon atoms. [0117]
  • Any hydroxyacid and related compound of the above three kinds may be used as an additive in a combination composition to enhance the percutaneous penetration or the therapeutic efficacy of cosmetic and pharmaceutical agents. The cosmetic and pharmaceutical agents may include but not limited to: age spots and keratoses removing agents, vitamins, aloes, retinoids, sun screens; tanning, depigmenting and shampooing agents; antiperspirants, antiyeasts, antifungal, antibacterial and antiviral agents; topical bronchial dilators; topical cardiovascular agents; keratoses, age spots and wrinkles removal agents, hair growth promoting agents and other dermatological agents. [0118]
  • Hydroxyacids and related compounds may also be used alone in the prophylactic and therapeutic treatment of cosmetic conditions or dermatologic disorders characterized by disturbed keratinization, aging, lipid metabolism or inflammation. The representative hydroxyacids are listed below: [0119]
  • citramalic acid, tropic acid, benzilic acid, ribonic acid and ribonolactone, gulonic acid and gulonolactone, 2,3,4-trihydroxybutanoic acid, 2,3,4,5-tetrahydroxypentanoic acid, 2,3,4,5,6-pentahydroxyhexanoic acid, 2-hydroxylauric acid, 2,3,4,5,6,7-hexahydroxyheptanoic acid, aleuritic acid, 4-hydroxymandelic acid, 4-chloromandelic acid, 2-hydroxy-3-methylbutanoic acid, 2-hydroxy-4-methylpentanoic acid, 3-hydroxy-3-methylbutanoic acid, 2-hydroxy-4-methylpentanoic acid, 3-hydroxy-4-methoxymandelic acid, 4-hydroxy-3-methoxymandelic acid, 3-(2-hydroxyphenyl) lactic acid, 3-(4-hydroxyphenyl) lactic acid, hexahydromandelic acid, 3-hydroxy-3-methylpentanoic acid, 1-hydroxy-1-cyclopropane carboxylic acid, 4-hydroxybutanoic acid, 2-hydroxyhexanoic acid, 5-hydroxylauric acid, 12-hydroxylauric acid, 10-hydroxydecanoic acid, 16-hydroxyhexadecanoic acid, 4-hydroxydecanoic acid, 5-hydroxydecanoic acid, and 4-hydroxy-2, 2-diphenylbutanoic acid. [0120]
  • Preparation of the Therapeutic Compositions
  • To prepare a therapeutic composition in solution form at least one of the aforementioned enhancing compounds of hydroxyacids and a cosmetic or pharmaceutical agent are dissolved in a solution which may consist of ethanol, water, propylene glycol, acetone or other pharmaceutically acceptable vehicles. The concentration of hydroxyacids may range from 0.01 to 99 percent by weight of the total composition. The concentration of the cosmetic or pharmaceutical agent ranges from 0.01 to 40 percent by weight of the total composition. [0121]
  • In the preparation of a therapeutic composition in cream or ointment form at least one of hydroxyacids and one of cosmetic or pharmaceutic agents are initially dissolved in a solvent such as water, ethanol, acetone, propylene glycol or polysorbate 80. the solution thus prepared is then mixed in a conventional manner with commonly available cream or ointment base such as hydrophilic ointment or petrolatum. The concentrations of hydroxyacids, cosmetic and pharmaceutical agents may range from 0.01 to 99 percent by weight of the total composition. [0122]
  • Therapeutic compositions of the instant invention may also be formulated in gel, lotion, shampoo, spray, stick or powder. A typical gel composition of the instant invention utilizes at least one of hydroxyacids and one of cosmetic or pharmaceutical agents dissolved in a mixture of ethanol, water and propylene glycol in a volume ratio of 40:40:20, respectively. A gelling agent such as hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose or ammoniated glycyrrhizinate is then added to the mixture with agitation. The preferred concentration of the gelling agent may range from 0.1 to 4 percent by weight of the total composition. [0123]
  • The following are illustrative examples of formulations and compositions according to this invention. Although the examples utilize only selected compounds and formulations, it should be understood that the following examples are illustrative and not limitative. Therefore, any of the aforementioned hydroxyacids, cosmetic and pharmaceutical agents may be substituted according to the teachings of this invention in the following examples. [0124]
  • EXAMPLE 1
  • A prophylactic and therapeutic composition in solution form for age spots and for keratoses may be prepared as follows. [0125]
  • Malic acid 1 gram, gluconolactone 19 grams and citric acid 0.5 gram are dissolved in a mixture of ethanol 30 ml, water 42 ml and glycerin 5 ml. Sodium bisulfite 0.5 g and hydroquinone 2 grams are added with stirring until a clear solution is obtained. The hydroxyacids, malic acid, gluconolactone and citric acid have been added a) as antioxidants to help stabilize the hydroquinone in the composition b) to enhance the penetration and the efficacy of hydroquinone c) to normalize the disturbed keratinization in age spot and keratoses. [0126]
  • The composition thus formulated contains 2% hydroquinone, 1% malic acid, 19% gluconolactone, 0.5% citric acid, and has pH 3.3 [0127]
  • EXAMPLE 2
  • A therapeutic composition in solution form for age spots and for keratoses may be formulated as follows. [0128]
  • Alpha hydroxyisobutyric acid (Methyllactic acid) 20 grams and citric acid 2 grams are dissolved in a mixture of ethanol 49 ml, water 20 ml and propylene glycol 7 ml. Sodium bisulfite 0.5 g and hydroquinone 2 grams are added with stirring until a clear solution is obtained. The composition thus formulated contains 2% hydroquinone, 2% citric acid, 20% methyllactic acid, and has pH 3.6. [0129]
  • EXAMPLE 3
  • A prophylactic and therapeutic composition containing minoxidil and lactic acid for hair growth and for prevention of hair loss on the scalp may be formulated as follows. [0130]
  • Minoxidil 2 grams and lactic acid 3 ml are dissolved in a mixture of ethanol 80 ml and propylene glycol 15 ml with stirring until a clear solution is obtained. The composition thus formulated contains 2% minoxidil, 3% lactic acid, and has pH 4.7. The lactic acid has been added to help minoxidil dissolved into solution, to enhance the penetration and the efficacy of minoxidil for hair growth. [0131]
  • EXAMPLE 4
  • A prophylactic and therapeutic composition in solution form for hair growth on the scalp may be formulated as follows. [0132]
  • Minoxidil 2 grams and ethyl pyruvate 2 ml are dissolved in a mixture of ethanol 80 ml and propylene glycol 16 ml. The composition thus formulated contains 2% minoxidil, 2% ethyl pyruvate, and has pH 5.0. The ketoacid ester, ethyl pyruvate has been added to enhance the penetration and the efficacy of minoxidil for hair growth on the scalp. [0133]
  • EXAMPLE 5
  • A therapeutic composition containing anthralin and hydroxyacid for psoriasis may be formulated as follows. [0134]
  • Anthralin powder 0.5 gram and alpha hydroxyisobutyric acid 4 grams are dissolved in a mixture of ethanol 50 ml, acetone 30 ml and diisopropyl adipate 16 ml with stirring until a clear yellowish solution is obtained. The composition thus formulated contains 0.5% anthralin, 4% alpha hydroxyisobutyric acid, and has pH 4.2. The hydroxyacid has been added to enhance the penetration and the efficacy of anthralin for psoriasis. [0135]
  • EXAMPLE 6
  • A therapeutic composition containing thionicotinamide and hydroxyacid for psoriasis, keratoses and warts may be formulated as follows. [0136]
  • Thionicotinamide 2 grams and lactic acid 20 ml are dissolved in a mixture of ethanol 40 ml, water 30 ml and propylene glycol 8 ml with stirring until a clear yellowish solution is obtained. The composition thus formulated contains 2% thionicotinamide, 20% lactic acid, and has pH 3.3. The lactic acid has been added to enhance the penetration and the efficacy of thionicotinamide, and also to normalize the disturbed keratinization in psoriasis, keratoses and warts. [0137]
  • EXAMPLE 7
  • A therapeutic composition containing 6-aminonicotinamide and hydroxyacid for psoriasis, keratoses and warts may be formulated as follows. [0138]
  • 6-Aminonicotinamide 1 gram and glycolic acid 19 grams are dissolved in a mixture of ethanol 40 ml, water 32 ml and propylene glycol 8 ml with stirring until a clear solution is obtained. The composition thus formulated contains 1% 6-aminonicotinamide, 19% glycolic acid, and has pH 3.0. The glycolic acid has been added to enhance the penetration and the efficacy of 6-Aminonicotinamide, and also to normalize the disturbed keratinization in psoriasis, keratoses and warts. [0139]
  • EXAMPLE 8
  • A therapeutic composition containing clotrimazole and hydroxyacid for fungal infection may be formulated as follows. [0140]
  • Clotrimazole 1 gram and lactic acid 4 ml are dissolved in 4 ml of ethanol, and the solution thus obtained is mixed with 91 grams of hydrophilic ointment USP. The mixing is continued until a uniform consistency is obtained. The composition thus formulated contains 1% clotrimazole, 4% lactic acid, and has pH 3.2. The lactic acid has been added to enhance the penetration and the efficacy of clotrimazole for athletes foot, and also to speed up healing and normalize the disturbed keratinization. [0141]
  • EXAMPLE 9
  • A prophylactic and therapeutic composition containing chlorhexidine and hydroxyacid as general antiseptics on skin, and for prophylactic and therapeutic treatment of acne may be formulated as follows. Chlorhexidine diacetate 1 gram and benzilic acid 5 grams are dissolved in a mixture of ethanol 70 ml, water 10 ml and propylene glycol 14 ml with stirring until a clear solution is obtained. The composition thus formulated contains 1% chlorhexidine, 5% benzilic acid, and has pH 4.4. Benzilic acid has been added to enhance the antibacterial effect of chlorhexidine, to eliminate the oiliness of the skin, and to improve the acne lesions. [0142]
  • EXAMPLE 10
  • A prophylactic and therapeutic composition containing benzilic acid as the only active ingredient for oily skin, acne, skin cleansing and skin malodor may be formulated as follows. [0143]
  • Benzilic acid 7 grams is dissolved in a mixture of ethanol 60 ml, water 20 ml and propylene glycol 13 ml with stirring until a clear solution is obtained. The composition thus prepared contains 7% benzilic acid, and has pH 3.0. [0144]
  • EXAMPLE 11
  • A therapeutic composition containing tropic acid as the only active ingredient for severe dry skin may be formulated as follows. [0145]
  • Tropic acid 10 grams is dissolved in 20 ml of ethanol, and the solution thus obtained is mixed with 70 grams of hydrophilic ointment USP. The mixing is continued until a uniform consistency is obtained. The composition thus formulated contains 10% tropic acid as an active ingredient, and has pH 3.7. [0146]
  • EXAMPLE 12
  • A prophylactic and therapeutic composition containing ribonolactone as the only active ingredient for oily skin, acne and skin cleansing may be formulated as follows. [0147]
  • Ribonolactone 4 grams is dissolved in a mixture of ethanol 36 ml and water 60 ml with stirring until a clear solution is obtained. The composition thus prepared contains 4% ribonolactone as an active ingredient, and has pH 3.8. [0148]
  • EXAMPLE 13
  • A therapeutic composition containing hydrocortisone and tropic acid for inflammatory and/or pruritic skin disorders may be formulated as follows. [0149]
  • Hydrocortisone 0.5 gram and tropic acid 5 grams are dissolved in 10 ml of ethanol and 4 ml of acetone, and the solution thus obtained is mixed with 80 grams of hydrophilic ointment USP. The mixing is continued until a uniform consistency is obtained. The composition thus formulated contains 0.5% hydrocortisone and 5% tropic acid as active ingredients, and has pH 3.4. The tropic acid has been added to enhance the penetration and the efficacy of hydrocortisone and also to normalize the disturbed keratinization. [0150]
  • EXAMPLE 14
  • A therapeutic composition containing triamcinolone acetonide and benzilic acid for eczema, psoriasis and other inflammatory and pruritic skin disorders may be formulated as follows. [0151]
  • Triamcinolone acetonide 0.1 gram and benzilic acid 5 grams are dissolved in 10 ml of ethanol, and the solution thus obtained is mixed with 85 grams of hydrophilic ointment USP. The mixing is continued until a uniform consistency is obtained. The composition thus formulated contains 0.1% triamcinolone acetonide, 5% benzilic acid, and has pH 3.4. The benzilic acid has been added to enhance the penetration and the efficacy of triamcinolone acetonide, and also to normalize the disturbed keratinization in eczema, psoriasis and other inflammatory skin disorders. [0152]
  • EXAMPLE 15
  • A prophylactic and therapeutic composition containing dipyridamole and lactic acid for hair growth and for prevention of hair loss on the scalp may be formulated as follows. [0153]
  • Dipyridamole 2 grams and lactic acid 4 ml are dissolved in a mixture of ethanol 80 ml and propylene glycol 14 ml with stirring until a clear yellowish solution is obtained. The composition thus formulated contains 2% dipyridamole, 4% lactic acid, and has pH 4.4. The lactic acid has been added to help dipyridamole dissolved into solution, to enhance the penetration and the efficacy of dipyridamole for hair growth and for preventing hair loss. [0154]
  • EXAMPLE 16
  • A therapeutic composition containing clobetasol propionate and agaricic acid for eczema, psoriasis and other inflammatory and pruritic skin disorders may be formulated as follows. [0155]
  • Agaricic acid fine powder 2 grams and 98 grams of clobetasol propionate cream are mixed until a uniform consistency is obtained. the composition thus formulated contains approximately 0.05% clobetasol propionate, 2% agaricic acid, and has pH 4.3. The agaricic acid has been added to enhance the penetration and the efficacy of clobetasol propionate, and also to normalize the disturbed keratinization in eczema, psoriasis and other inflammatory skin disorders. [0156]
  • EXAMPLE 17
  • A therapeutic composition containing betamethasone dipropionate and benzilic acid for eczema, psoriasis, contact dermatitis and other inflammatory and pruritic skin disorders may be formulated as follows. [0157]
  • Benzilic acid powder 5 grams and 95 grams of betamethasone dipropionate ointment are mixed until a uniform consistency is obtained. the composition thus formulated contains approximately 0.05% betamethasone dipropionate and 5% benzilic acid. The benzilic acid has been added to enhance the penetration and the efficacy of betamethasone dipropionate, and also to normalize the disturbed keratinization in eczema, psoriasis and other inflammatory skin disorders. [0158]
  • EXAMPLE 18
  • A prophylactic and therapeutic composition containing aloe, malic acid and gluconolactone for oily skin and acne may be formulated as follows. [0159]
  • Aloe powder 200 fold 0.2 gram and ammoniated glycyrrhizinate 2 grams are mixed with water 61 ml and propylene glycol 2 ml. The mixture is heated to 50° C. until the aloe powder and the ammoniated glycyrrhizinate are completely dissolved. Ethanol 10 ml is added to the solution followed by the addition of partially neutralized malic acid stock solution 3 ml and gluconolactone stock solution 22 ml with stirring. The warm solution is poured into container jars before cooling. The gel composition thus formulated contains 40% aloe, 1% malic acid, 9% gluconolactone, and has pH 4.0. Malic acid and gluconolactone have been added to enhance the skin softness and smoothness by aloe, and also to normalize any disturbed keratinization of the skin. [0160]
  • EXAMPLE 19
  • A sun screen composition containing octyl dimethyl PABA, dioxybenzone and lactic acid may be formulated as follows. Octyl dimethyl PABA $ grams, dioxybenzone 3 grams and lactic acid 2 ml. are dissolved in a mixture of ethanol 65 ml, water 10 ml and propylene glycol 15 ml with stirring until a clear solution is obtained. The composition thus formulated contains 5% octyl dimethyl PABA, 3% dioxybenzone, 2% lactic acid, and has pH 3.6. The lactic acid has been added to substantiate the absorption of sunscreen agents, octyl dimethyl PABA and dioxybenzone, and to enhance the sun screen effect. [0161]
  • EXAMPLE 20
  • A prophylactic and therapeutic composition containing tetracycline and glycolic acid for oily skin and acne may be formulated as follows. [0162]
  • Tetracycline 3 grams and glycolic acid 5 grams are dissolved in a mixture of ethanol 40 ml, water 40 ml and propylene glycol 12 ml with stirring until the tetracycline and glycolic acid are completely dissolved. The composition thus formulated contains 3% tetracycline, 5% glycolic acid, and has pH 3.4. The glycolic acid has been added to help tetracycline dissolved into the solution, to enhance the penetration and the efficacy of tetracycline, and to normalize the disturbed keratinization in acne. [0163]
  • EXAMPLE 21
  • A therapeutic composition containing griseofulvin and methyl pyruvate for fungal infection of nails may be formulated at follows. [0164]
  • Griseofulvin 1 gram and methyl pyruvate 2 ml are dissolved in a mixture of 2-pyrrolidone 20 ml. PEG-400 47 ml and ethanol 30 ml with stirring until the griseofulvin is completely dissolved. The composition thus formulated contains 1% griseofulvin, 2% methyl pyruvate, and has pH 4.4. The methyl pyruvate has been added to help griseofulvin dissolve into the solution, to enhance the penetration and the efficacy of griseofulvin, and to normalize the disturbed keratinization in nails. [0165]
  • EXAMPLE 22
  • A therapeutic composition containing lidocaine and atrolactic acid for pruritic skin may be formulated as follows. [0166]
  • Lidocaine 2 grams and atrolactic acid hemihydrate 3 grams are dissolved in a mixture of ethanol 40 ml, water 40 ml and propylene glycol 15 ml with stirring until the lidocaine and atrolactic acid are completely dissolved. The composition thus formulated contains 2% lidocaine, 3% atrolactic acid, and has pH 4.6. The atrolactic acid has been added to help lidocaine dissolved and stabilized in the solution and to enhance the efficacy of lidocaine for pruritic skin. [0167]
  • EXAMPLE 23
  • A prophylactic and therapeutic composition containing retinoic acid and ethyl pyruvate for oily skin and acne may be formulated as follows. [0168]
  • Retinoic acid, all-trans 0.1 gram and ethyl pyruvate 2 ml are dissolved in a mixture of ethanol 80 ml, water 10 ml and propylene glycol 8 ml with stirring until a yellowish solution is obtained. The composition thus formulated contains 0.1% vitamin A acid, 2% ethyl pyruvate, and has pH 3.6. The ethyl pyruvate has been added to enhance the penetration and the efficacy of retinoic acid, and to normalize the disturbed keratinization in acne. [0169]
  • EXAMPLE 24
  • A prophylactic and therapeutic composition containing erythromycin and aleuritic acid for oily skin and acne may be formulated as follows. [0170]
  • Erythromycin 2 grams and aleuritic acid 2 grams are dissolved in a mixture of ethanol 50 ml, water 40 ml and propylene glycol 6 ml with stirring until a clear solution is obtained. The composition thus formulated contains 2% erythromycin, 2% aleuritic acid, and has pH 5.7. The aleuritic acid has been added to help erythromycin dissolve into the solution, to enhance the penetration and the efficacy of erythromycin, and to normalize the disturbed keratinization in acne. [0171]
  • EXAMPLE 25
  • A therapeutic composition containing P-hydroxymandelic acid for dry skin may be formulated as follows. [0172]
  • P-Hydroxymandelic acid 10 grams is dissolved in 20 ml of ethanol, and the pinkish solution thus obtained is mixed with 70 grams of hydrophilic ointment USP with stirring until a uniform consistency is obtained. The composition thus formulated contains 10% P-hydroxymandelic acid as an active ingredient, and has pH 3.2. P-Hydroxymandelic acid has been incorporated into the composition to alleviate any scaly or flaky skin, and to change the dry skin into normal smooth and soft skin. [0173]
  • EXAMPLE 26
  • A therapeutic composition containing hydroquinone and lactic acid in solution form for age spots, keratoses, melasmas, lentigines and other pigmented skin spots may be formulated as follows. [0174]
  • Lactic acid 10 ml, hydroquinone 4 grams and sodium metabisulfite 0.6 gram are dissolved in a mixture of ethanol 70 ml, water 10 ml and propylene glycol 6 ml with stirring until a clear solution is obtained. The composition thus formulated contains 4% hydroquinone, 10% lactic acid, and has pH 4.0. The lactic acid has been added to help stabilize and enhance the penetration and the efficacy of hydroquinone, and also to normalize the disturbed keratinization in the skin lesions. The composition thus formulated is packaged in felt pens for controlled delivery to skin lesions. [0175]
  • EXAMPLE 27
  • A therapeutic composition containing hydroquinone and glycolic acid in solution form for age spots, keratoses, melasmas, lentigines and other pigmented skin spots may be formulated as follows. [0176]
  • Glycolic acid 8 grams, hydroquinone 5 grams and sodium metabisulfite 0.5 gram are dissolved in a mixture of ethanol 70 ml, water 10 ml and propylene glycol 7 ml with stirring until a clear solution is obtained. The composition thus formulated contains 5% hydroquinone, 8% glycolic acid, and has pH 3.9. The glycolic acid has been added to help stabilize and enhance the penetration and the efficacy of hydroquinone, and also to normalize the disturbed keratinization in the skin lesions. The composition thus prepared is packaged in felt pens for controlled delivery to skin lesions. [0177]
  • EXAMPLE 28
  • A therapeutic composition containing hydroquinone and 2-methyl 2-hydroxypropanoic acid in solution form for age spots, keratoses, melasmas, lentigines and other pigmented skin spots may be formulated as follows. [0178]
  • 2-Methyl 2-hydroxypropanoic acid 12 grams, hydroquinone 4 grams and sodium bisulfite 0.3 gram are dissolved in a mixture of ethanol 60 ml, water 20 ml and propylene glycol 4 ml with stirring until a clear solution is obtained. The composition thus formulated contains 4% hydroquinone, 12% 2-methyl 2-hydroxypropanoic acid, and has pH 4.0. The composition solution is packaged in felt pens for controlled delivery to skin lesions. The 2-methyl 2-hydroxypropanoic acid has been added to help stabilize and enhance the penetration and the efficacy of hydroquinone, and also to normalize the disturbed keratinization in the skin lesions. [0179]
  • EXAMPLE 29
  • A composition containing hydroquinone alone in solution form for age spots and keratoses studies may be formulated as follows. [0180]
  • Hydroquinone 5 grams and sodium metal bisulfite 0.5 gram are dissolved in a mixture of ethanol 70 ml, water 15 ml and propylene glycol 10 ml with stirring until a clear solution is obtained. The composition thus prepared contains 5% hydroquinone and has pH 6.0. The composition solution is packaged in felt pens for comparative studies; with or without hydroxyacids on age spots and keratoses. [0181]
  • Test Results
  • In order to determine whether addition of a hydroxyacid in the composition could enhance the therapeutic action of a cosmetic or pharmaceutical agent a total of more than 55 volunteers and patients having different skin disorders participated in these studies. Each participating subject was given two preparations; i.e. with or without the addition of a hydroxyacid in the therapeutic composition. [0182]
  • Topical applications were carried out either by bilateral or sequential comparison, In bilateral comparison the subject was instructed to apply one preparation on one side of the body and the other one on the other side of the body. For psoriasis, eczema, severe dry skin, athlete's foot, etc., where both sides were involved, the subject was instructed to apply two to three times daily one medication on one side of the body for a period of up to several months of time. In the pulse treatment for psoriasis or other inflammatory diseases the medication was applied only once every three days or twice a week. The medication was discontinued whenever a total remission of the gin lesions occurred prior to the test period of up to several months. [0183]
  • For the scalp or face involvement such as in dandruff, oily skin, acne and seborrheic dermatitis the subject was instructed to apply two to three time daily one medication on one side of the scalp or the face and the other medication on the other side of the scalp or the face for a period of up to 12 weeks of time. For age spots, keratoses or warts the medication was continued for up to 4 months of time. [0184]
  • Sequential administrations of medications were carried out whenever the bilateral comparison was difficult. for example in pruritic conditions the subject was instructed to apply four time daily or as often as necessary one medication on the pruritic, lesions for two days, then switched to the other medication on the same lesions for another two days, thus to compare which medication was more effective in relieving the itching. [0185]
  • 1. Dry skin. [0186]
  • Human subjects having ordinary dry skin or with moderate degrees of dry skin as evidenced by dry, flaking and cracking of the skin were instructed to apply topically the lotion, cream or ointment containing 3 to 7 percent of hydroxyacids of the instant invention on the affected skin areas. Topical application, two to three times daily, was continued for two to three weeks. In all the nine subjects tested, the feeling of the skin dryness disappeared within a week of topical application. The rough and cracked skin became less pronounced and the skin appeared normal and felt smooth after 10 days of topical treatment. [0187]
  • The ordinary dry skin conditions once restored to normal appearing skin remained improved for some time until causes of dry skin, such as low humidity, cold weather, excessive contact pressure, detergents, soaps,'solvents, chemicals, etc., again caused recurrence of the dry skin condition. On continued use it was also found that twice daily topical application of a composition containing one or more hydroxyacids of instant invention prevented the development of new dry skin lesions. [0188]
  • In severe dry skin the skin lesions are different from the above. The involved skin is hyperplastic, fissured and has thick adherent scales. The degree of thickening is such that lesions are palpably and visually elevated. The thickened adherent scales cause the surface of involved skin to be markedly rough and uneven. The two attributes of thickness and texture can be quantified to allow objective measurement of degree of improvement from topically applied therapeutic test materials as follows: [0189]
    DEGREE OF IMPROVEMENT
    None Mild Moderate Substantial Complete
    (0) (1+) (2+) (3+) (4+)
    THICKNESS Highly Detectable Readily Barely Normal
    elevated reduction apparent elevated thickness
    reduction
    TEXTURE Visibly Palpably Uneven but Slightly Visibly and
    rough rough not rough uneven palpably
    smooth
  • By means of such parameters degrees of change in lesions can be numerically noted and comparisons made of one treated site to another. [0190]
  • In order to evaluate the hydroxyacids and their related compounds of the instant invention a total of six patients with severe dry skin conditions or ichthyosis were treated with the compositions containing 7 to 15% of hydroxyacids as described in the Examples. [0191]
  • Treated areas were of a size convenient for topical applications, i.e., circles 5 cm in diameter demarcated with a plastic ring of that size inked on a stamp pad. The medicinal creams or ointments were topically applied by the patient in an amount sufficient to cover the treatment sites. Applications were made three time daily and without occlusive dressings. Applications were discontinued at any time when resolution of the lesion on the treatment area was clinically judged to be complete. [0192]
  • The test results on patients with severe dry skin are summarized on the following table. [0193]
    Topical Effectiveness of Hydroxyacids on Severe Dry Skin
    Number of Therapeutic
    Compounds Patients Effectiveness
    1. Tropic acid 4 4+
    2. Benzilic acid 5 4+
    3. Ribonolactone 3 3+
    4. 4-Hydroxymandelic acid 2 3+
    5. 3-Chloro 4-hydroxymandelic acid 2 3+
    6. 3,4-Dihydroxymandelic acid 2 3+
  • 2. Psoriasis [0194]
  • The involved skin in psoriasis is hyperplastic (thickened), erythematous (red or inflamed), and has thick adherent scales. the degree of thickening is such that lesions are elevated up to 1 mm above the surface of adjacent normal skin; erythema is usually an intense red; the thickened adherent scales cause the surface of involved skin to be markedly rough and uneven. These three attributes of thickness, color and texture can be quantified to allow objective measurement of degree of improvement from topically applied therapeutic test materials as follows. [0195]
    DEGREE OF IMPROVEMENT
    None Mild Moderate Substantial Complete
    (0) (1+) (2+) (3+) (4+)
    Thickness Highly Detectable Readily Barely Normal
    elevated reduction apparent elevated thickness
    Texture Visibly Palpably Uneven but Slightly Visibly and
    rough rough not rough uneven palpably smooth
    Color Intense Red Dark Pink Light Normal skin
    red pink color
  • By means of such parameters degree of improvements in psoriatic lesions can be numerically recorded and comparisons made of one treated site to another. The treatment schedule was quite different from the previously described in that the present study was employing a “Pulse Treatment.” Instead of several times daily application the therapeutic composition of antipsoriatic agent with or without a hydroxyacid in solution form was topically applied to the involved skin only once in every three days or twice a week. The test results on patients having psoriasis are summarized on the following table. [0196]
    Topical Effects on Psoriasis of Antipsoriatic Agents
    With or without Hydroxyacids
    Thera-
    Number peutic
    of Effective-
    Compositions Patients ness
    Thionicotinamide 3% alone 6 2+
    with 10% Lactic acid 6 4+
    with 5% Glycolic acid 4 4+
    with 5% 2-methyl 2-hydroxypropanoic acid 3 4+
    6-Aminonicotinamide 1% alone 5 3+
    with 10% Lactic acid 5 4+
    with 10% Glycolic acid 4 4+
    Betamethasone dipropionate 0.05% ointment alone 5 3+
    with 5% Benzilic acid 4 −4+ 
    with 5% Tropic acid 3 4+
    with 5% 2-Methyl 2-Hydroxypropanoic acid 3 4+
    Clobetasol propionate 0.05% cream alone 4 2+
    with 5% Benzilic acid 3 3+
    with 5% Tropic acid 2 3+
    with 5% 2-Methyl 2-hydroxypropanoic acid 3 3+
  • In a topical treatment of eczema patients, betamethasone dipropionate or clobetasol propionate alone at 0.05% would achieve only a 3+ improvement on all the eczema patients tested. As shown by the table with the additional of 5% gluconolactone or ribonolactone betamethasone dipropionate or clobetasol propionate could attain a 4+ maximal clearing on all the eczema patients tested. [0197]
    Topical Effects on Eczema of Corticosteroids
    With and Without Hydroxyacid Lactone
    Number of Therapeutic
    Composition Patients Effectiveness
    Betamethasone dipropionate 0.05% alone 3 3+
    with 5% Gluconolactone 3 4+
    with 5% Ribonolactone 2 4+
    Clobetasol propionate 0.05% alone 4 3+
    with 5% Gluconolactone 4 4+
    with 5% Ribonolactone 3 4+
  • 3. Age Spots, Wrinkles, Keratoses and Pigmented Skin lesions. [0198]
  • Therapeutic compositions packaged in felt pens as described in Examples were provided to 14 patients for treatment of age spots, wrinkles, keratoses and other pigmented skin spots. Each participating patient received two felt pens; i.e. with or without the addition of hydroxyacid to the composition containing hydroquinone. The patients were instructed to apply topically one medication on one side of the body such as on the back of the left hand and the other medication on the other side of the body such as on the back of the right hand. Specific instructions were given to the patients that the medications were applied twice daily and discretely only to the skin lesions of age spots, wrinkles, keratoses, melasmas, lentigines or other pigmented skin spots. [0199]
  • Within one to three weeks, improvement of age spots and keratoses was clinically discernible. After one to three months substantial eradication of age spots, wrinkles and keratoses occurred in all the patients tested. Complete eradication of age spots usually occurred within two to four months of topical administration in most cases. Therapeutic compositions containing higher concentrations of hydroxyacids (10 to 20%) and hydroquinone (3 to 5%) were judged to be more efficient in eradicating age spots, wrinkles and keratoses within shorter periods of time. Without the addition of a hydroxyacid to the composition of hydroquinone, eradication of age spots, wrinkles or keratoses did not occur within four months of time. [0200]
  • It was also found that while compositions containing hydroxyacids without hydroquinone were effective for eradication of keratoses and wrinkles, the compositions were not efficient in eradicating pigmented age spots, melasmas or lentigines within 4 months of time. In any case, with the addition of a hydroxyacid to the composition containing hydroquinone, pigmented age spots, melasmas, lentigines and other pigmented skin spots had been substantially eradicated. [0201]
  • 4. Acne. [0202]
  • Therapeutic compositions containing tetracycline, erythromycin or chlorhexidine with or without the addition of a hydroxyacid were provided to 9 patients having papulopustular or pustular lesions of acne. Each participating patient received two medications, with or without the addition of a hydroxyacid to the composition containing an antibiotic. The patients were instructed to apply topically one medication on one side of the body such as the left side forehead, face, back or chest, and the other medication on the other side of the body such as right side forehead, face, back or chest. Twice daily administration was continued for 4 to 12 weeks. [0203]
  • The degree and rate of improvement on acne lesions were clinically evaluated, and comparison was made between the two sides; one side with and the other side without a hydroxyacid in the compositions containing an antibiotic. It was found that the degree and rate of improvement on acne lesions were substantially better on the side treated with a combination composition containing both the hydroxyacid and the antibiotic as compared to that of the antibiotic alone. The time for complete clearing of acne lesions treated with a combination composition varied from 4 to 12 weeks of time, with an average time of 8 weeks, whereas complete clearing with that of the antibiotic alone ranged from 8 weeks to 9 months, with an average of 4 months. [0204]
  • 5. Preventing Hair Loss and for Hair Growth. [0205]
  • Prophylactic and therapeutic compositions containing minoxidil or dipyridamole with or without a hydroxyacid or related compound were provided to 6 human subjects having a progressive loss of hair on the scalp. Each participating subject received two medications; i.e. with or without the addition of a hydroxyacid to the composition containing minoxidil or dipyridamole. The subjects were instructed to apply topically one medication on one side of the scalp and the other medication on the other side of the scalp. Twice daily topical applications were continued for 2 to 6 months. Clinical evaluation shows that the combination compositions containing minoxidil or dipyridamole and a hydroxyacid or related compound were therapeutically more efficient in preventing the hair loss and enhancing hair growth on the scalp. [0206]
  • Therapeutic compositions containing clotrimazole or griseofulvin with or without the addition of a hydroxyacid were provided to 6 patients having recurrent fungal infections of the foot; i.e. athlete's foot with or without toe nail involvement. Each participating patient received two medications with or without the addition of a hydroxyacid to the composition containing clotrimazole or griseofulvin. The patients were instructed to apply topically one medication on one side of the body such as left foot, and the other medication on the other side of the body such as right foot. Three time daily applications were continued for one to two weeks. When nail infections were involved the topical application was continued for up to 4 months using the compositions containing griseofulvin with or without the addition of a hydroxyacid. [0207]
  • The degree and rate of improvement on skin lesions were clinically evaluated, and comparison was made one side of the body against the other. It was found that the skin lesions improved much faster with the compositions containing both the antifungal agent and the hydroxyacid. The presence of hydroxyacid appeared to enhance the efficacy of the antifungal agent, and also to eliminate the discomforts such as itching, tingling, burning and heat due to the fungal infection. Generally the infected skin healed within a week from topical application of the compositions containing an antifungal agent and a hydroxyacid. When toe nails were involved in the fungal infection the complete healing and regrowth of nails usually took several months on continued topical application of medications containing griseofulvin and a hydroxyacid. [0208]
  • The hydroxyacids and related compounds which may be useful as dermatologic agents for various conditions and disorders including age spots, keratoses, skin wrinkles etc. or as additives to enhance therapeutic effects of other cosmetic or pharmaceutical agents include 2-Hydroxyacetic acid; 2-hydroxypropanoic acid; 2-methyl 2-hydroxypropanoic acid: 2-hydroxybutanoic acid; phenyl 2-hydroxyacetic acid; phenyl 2-methyl 2-hydroxyacetic acid; 3-phenyl 2-hydroxyacetic acid; 2,3-dihyroxypropanoic acid; 2,3,4-trihydroxybutanoic acid; 2,3,4,5,6-pentahydroxyhexanoic acid; 2-hydroxydodecanoic acid; 2,3,4,5-tetrahydroxypentanoic acid; 2,3,4,5,6,7-hexahydroxyheptanoic acid; diphenyl 2-hydroxyacetic acid; 4-hydroxymandelic acid; 4-chloromandelic acid; 3-hydroxybutanoic acid; 4-hydroxybutanoic acid; 2-hydroxyhexanoic acid; 5-hydroxydodecanoic acid; 12-hydroxydodecanoic acid; 10-hydroxydecanoic acid; 16-hydroxyhexadecanoic acid; 2-hydroxy-3-methylbutanoic acid; 2-hydroxy-4-methylpentanoic acid; 3-hydroxy-4-methoxymandelic acid; 4-hydroxy-3-methoxymandelic acid; 2-hydroxy-2-methylbutanoic acid; 3-(2-hydroxphenyl) lactic acid; 3-(4-hydroxyphenyl) lactic acid; hexahydromandelic acid; 3-hydroxy-3-methylpentanoic acid; 4-hydroxydecanoic acid; 5-hydroxydecanoic acid; aleuritic acid. 2-Hydroxypropanedioic acid; 2-hydroxybutanedioic acid; erythraric acid; threaric acid; arabiraric acid; ribaric acid; xylaric acid; lyxaric acid; glucaric acid; galactaric acid; mannaric acid; gularic acid; allaric acid; altraric acid; idaric acid; talaric acid; 2-hydroxy-2-methylbutanedioic acid. [0209]
  • Citric acid, isocitric acid, agaricic acid, quinic acid, glucuronic acid, glucuronolactone, galacturonic acid, galacturonolactone, uronic acids, uronolactones, ascorbic acid, dihydroascorbic acid, dihydroxytartaric acid, tropic acid, ribonolactone, gluconolactone, galactonolactone, gulonolactone, mannonolactone, citramalic acid. [0210]
  • Pyruvic acid, hydroxypyruvic acid, hydroxypyruvic acid phosphate, their esters; methyl pyruvate, ethyl pyruvate, propyl pyruvate, isopropyl pyruvate; phenyl pyruvic acid, its esters; methyl phenyl pyruvate, ethyl phenyl pyruvate, propyl phenyl pyruvate; formyl formic acid; its esters; methyl formyl formate, ethyl formyl formate, propyl formyl formate; benzoyl formic acid, its esters; methyl benzoyl formate, ethyl benzoyl formate and 3 propyl benzoyl formate; 4-hydroxybenzoyl formic acid, its esters; 4-hydroxyphenyl pyruvic acid, its esters; 2-hydroxyphenyl pyruvic acid and its esters. [0211]
  • The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The present embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims and all changes which come within the meaning and equivalency of the claims are therefore intended to be embraced therein. [0212]

Claims (35)

    What is claimed is:
  1. 1. A method for enhancing the therapeutic effect of a composition comprising a cosmetic or pharmaceutical agent in a pharmaceutically acceptable vehicle for topical application to the skin of humans or animals comprising:
    admixing with said composition an enhancing effective amount of at least one member selected from the group consisting of hydroxycarboxylic acid and related ketocarboxylic acid and ester, lactone or salt forms thereof.
  2. 2. The method of
    claim 1
    wherein said cosmetic or pharmaceutical agent is a member selected from the group consisting of age spots, wrinkles and keratoses removing agents; analgesics, anesthetics, antiacne agents, antibacterials, antiyeasts, antifungals, antivirals; antiburn, antidandruff, antidermatitis, antipruritic, antiperspirant, antiinflammatory, antiaging, antihyperkeratolytic, antidryskin, antipsoriasis, antiseborrhea, astringent agents; skin softeners and emollients; coal tar, bath oils, sulfur, rinse conditioners; hair growth and hair removing agents; keratolytics, moisturizers, powders, shampoos, skin bleaches, skin protectants, soaps, cleansers, sunscreens, wart removers, vitamins, tanning agents; topical antihistamins, hormones, retinoids, vasodilators, bronchial dilators, topical cardiovasculars and dermatologicals.
  3. 3. The method of
    claim 1
    wherein said cosmetic or pharmaceutical agent is a member selected from the group consisted of: aloe; 9-aminoacridine; PABA and its esters, acyclovir, amphotericins; benzoyl peroxide; clindamycin, chloramphenicol; clotrimazole, candicidin; cromolyn, clindamycin, crotamiton, coal tar; doxycycline; dipyridamole, dioxybenzone, diazoxide, diphenylhydantoin; ephedrine, erythromycin; fluorouracil, flucytosine; gentamicin, griseofulvin, gramicidin; halothane, hydroquinone and its monomethyl and benzyl ethers; haloprogin, hydralazine; idoxuridine, kanamycin, ketoconazole, lidocaine, miconazole, metronidazole, minoxidil, minocycline, meclocycline, metronidazole, nitroglycerine, nystatin, neomycin, oxybenzone, oxytetracycline, procaine, polymyxins, povidone-iodine, phenytoin, prazosin, retinoic acid and other retinoids, spironolactone, sulfonamides, sulfacytosine, spectinomycin, sulfamethoxazole, sulfisoxazoles, sulfamethizole, salicylic acid, selenium sulfide, sulfer, theophylline, tobramycin, tetracycline, tolnaftate, trimethoprin, troleandomycin, vitamins, vancomycin and zinc pyrithione.
  4. 4. The method of
    claim 1
    wherein said hydroxycarboxylic acid is hydroxymonocarboxylic acid having the following chemical structural formula:
    R1(CR2OH)m(CH2)nCOOH
    wherein
    R1, R2=H, alkyl, aralkyl or aryl group of saturated or unsaturated, straight or branched chain or cyclic form, having 1 to 25 carbon atoms.
    m=1,2,3,4,5,6,7,8 or 9
    n=0 or a numerical number up to 23
    present as free acid, lactone or salt form, and as optically active or inactive isomer such as D, L, and DL forms; the hydrogen atom attached to the carbon atom may be substituted by a nonfunctional F, Cl, Br, I, or S atom or a lower alkyl or alkoxy saturated or unsaturated radical, having 1 to 9 carbon atoms.
  5. 5. The method of
    claim 4
    wherein said hydroxymonocarboxylic acid is a member selected from the group consisted of 2-hydroxyacetic acid; 2-hydroxypropanoic acid; 2-methyl 2-hydroxypropanoic acid; 2-hydroxybutanoic acid; phenyl 2-hydroxyacetic acid; phenyl 2-methyl 2-hydroxyacetic acid; 3-phenyl 2-hydroxypropanoic acid; 2,3-dihydroxypropanoic acid; 2,3,4-trihydroxybutanoic acid; 2,3,4,5-tetrahydroxypentanoic acid; 2,3,4,5,6-pentahydroxyhexanoic acid; 2-hydroxydodecanoic acid; 2,3,4,5,6,7-hexahydroxyheptanoic acid; diphenyl 2-hydroxyacetic acid; 4-hydroxymandelic acid; 4-chloromandelic acid; 3-hydroxybutanoic acid; 4-hydroxybutanoic acid; 2-hydroxyhexanoic acid; 5-hydroxydodecanoic acid; 12-hydroxydodecanoic acid; 10-hydroxydecanoic acid; 16-hydroxyhexadecanoic acid; 2-hydroxy-3-methylbutanoic acid; 2-hydroxy-4-methylpentanoic acid; 3-hydroxy-4-methoxymandelic acid; 4-hydroxy-3-methoxymandelic acid; 2-hydroxy-2-methylbutanoic acid; 3-(2-hydroxyphenyl) lactic acid; 3-(4-hydroxyphenyl) lactic acid; hexahydromandelic acid; 3-hydroxy-3-methylpentanoic acid; 4-hydroxydecanoic acid; 5-hydroxydecanoic acid; aleuritic acid.
  6. 6. The method of
    claim 4
    wherein said hydroxymonocarboxylic acid is a member derived from an amino acid by substituting the amino group with a hydroxy group.
  7. 7. The method of
    claim 4
    wherein said lactone is an intermolecular or intramolecular lactone including linear acid polymer, ribonolactone, gluconolactone, galactonolactone, gulonolactone and mannonolactone.
  8. 8. The method of
    claim 1
    wherein said compound is a keto or hydroxyketomonocarboxylic acid selected from the group consisting of pyruvic acid, hydroxypyruvic acid, hydroxypyruvic acid phosphate, methyl pyruvate, ethyl pyruvate, propyl pyruvate, isopropyl pyruvate, phenyl pyruvic acid, methyl phenyl pyruvate, ethyl phenyl pyruvate, propyl phenyl pyruvate; formyl formic acid, methyl formyl formate, ethyl formyl formate, propyl formyl formate, benzoyl formic acid, methyl benzoyl formate, ethyl benzoyl formate, propyl benzoyl formate, 4-hydroxybenzoyl formic acid, 4-hydroxyphenyl pyruvic acid, and 2-hydroxyphenyl pyruvic acid.
  9. 9. The method of
    claim 1
    wherein said compound is a hydroxydicarboxylic acid having the following chemical structural formula:
    Figure US20010016604A1-20010823-C00002
    wherein
    m=1,2,3,4,5,6,7,8, or 9
    n=0 or a numerical number up to 23
    present as free acid, lactone or salt form, and as optically active or inactive D, L, and meso isomer; hydrogen atom attached to the carbon atom may be substituted by a nonfunctional F, Cl, Br, I, or S atom or a lower alkyl or alkoxy saturated or unsaturated radical, having 1 to 9 carbon atoms.
  10. 10. The method of
    claim 9
    wherein said hydroxydicarboxylic acid is a member selected from the group consisted of 2-hydroxypropanedioic acid; 2-hydroxybutanedioic acid; erythraric acid; threaric acid; arabiraric acid; ribaric acid; xylaric acid; lyxaric acid; glucaric acid; galactaric acid; mannaric acid; gularic acid; allaric acid; altraric acid; idaric acid; talaric acid; 2-hydroxy-2-methylbutanedioic acid.
  11. 11. The method of
    claim 9
    wherein said hydroxydicarboxylic acid is a member derived from an amino acid by substituting the amino group with a hydroxy group.
  12. 12. The method of
    claim 9
    wherein said lactone is an intermolecular or intra molecular lactone including saccharic acid, 1,4-lactone.
  13. 13. A method for enhancing the therapeutic effect of a composition comprising a cosmetic or pharmaceutical agent in a pharmaceutically acceptable vehicle for topical application to the skin of humans or animals comprising:
    admixing with said composition an enhancing effective amount of at least one member selected from the group consisting of
    Hydroxycarboxylic acid of
    R(OH)m(COOH)n
    Wherein m,n=1,2,3,4,5,6,7,8 or 9
    R=H, alkyl, aralkyl or aryl group of saturated or unsaturated, straight or branched chain or cyclic form, having 1 to 25 carbon atoms.
    citric acid, isocitric acid, agaricic acid, quinic acid, citramalic acid, glucuronic acid, glucuronolactone, galacturonic acid, galacturonolactone, uronic acids, uronolactones, ascorbic acid, dihydroascorbic acid, dihydroxytartaric acid, 1-hydroxy-1-cyclopropanecarboxylic acid, 2-hydroxyhexanedial, 5-hydroxylysine, 3-hydroxy-2-aminopentanoic acid, 4-hydroxy-3-pentenoic acid, tropic acid, 4-hydroxy-2, 2-diphenylbutanoic acid, and 3-hydroxy-3-methylglutaric acid and ester, lactone or salt forms thereof, and as an optically active or inactive D, L, DL or meso isomer; the hydrogen atom attached to the carbon atom may be substituted by a nonfunctional F, Cl, Br, I or S atom or a lower alkyl or alkoxy saturated or unsaturated radical having 1. to 9 carbon atoms.
  14. 14. The method of
    claim 13
    wherein the lactone is an inter or intramolecular lactone.
  15. 15. A therapeutic composition effective against skin conditions and disorders comprising an effective amount of at least one compound selected from the group consisting of:
    Citramalic acid, Diphenyl 2-hydroxyacetic acid (benzilic acid), 2-phenyl 3-hydroxypropanoic acid (tropic acid), aleuritic acid, ribonic acid, ribonoloactone, 2,3,4-trihydroxybutanoic -acid, 2,3,4,5-tetrahydroxypentanoic acid, 2,3,4,5,6-pentahydroxyhexanoic acid, 2-hydroxylauric acid, 2,3,4,5,6,7-hexahydrokyheptanoic acid, 4-hydroxymandelic acid, 4-chloromandelic acid, 2-hydroxy-3-methylbutanoic acid, 2-hydroxy-4-methylpentanoic acid, 3-hydroxy-4-methoxymandelic acid, 4-hydroxy-3-methoxymandelic acid, 3-(3-hyroxphenyl) lactic acid, 3-(4-hydroxyphenyl) lactic acid, hexahydromandelic acid, 3-hydroxy-3-methylpentanoic acid, 1-hydroxy-1-cyclopropane carboxylic acid, 4-hydroxybutanoic acid, 2-hydroxyhexanoic acid, 5-hydroxylauric acid, 12-hydroxylauric acid, 10-hydroxydecanoic acid, 16-hydroxyhexadecanoic acid, 4-hydroxydecanoic acid, 5-hydroxydecanoic acid, and 4-hydroxy-2, 2-diphenylbutanoic acid. as a free acid or salt form in a pharmaceutically or cosmetically acceptable vehicle.
  16. 16. The composition of
    claim 15
    wherein said skin conditions and disorders include dry skin, dandruff, keratoses, age spots, warts, acne, oily skin, eczema, psoriasis, wrinkles, inflammatory and pruritic skin, and disturbed keratinization.
  17. 17. A method for alleviating the symptoms of skin conditions and disorders comprising the topical application of a therapeutic effective amount of at least one compound selected from the group consisting of:
    Diphenyl 2-hydroxyacetic acid (benzilic acid), 2-phenyl 3-hydroxypropanoic acid (tropic acid), aleuritic acid, ribonic acid, ribonoloactone, 2,3,4-trihydroxybutanoic acid, 2,3,4,5-tetrahydroxypentanoic acid, 2,3,4,5,6-pentahydroxyhexanoic acid, 2-hydroxylauric acid, 2,3,4,5,6,7-hexahydroxyheptanoic acid, 4-hydroxymandelic acid, 4-chloromandelic acid, 2-hydroxy-3-methylbutanoic acid, 2-hydroxy-4-methylpentanoic acid, 3-hydroxy-4-methoxymandelic acid, 4-hydroxy-3-methoxymandelic acid, 3-(2-hydroxphenyl) lactic acid, citramalic acid, 3-(4-hydroxyphenyl) lactic acid, hexahydromandelic acid, 3-hydroxy-3-methylpentanoic acid, 1-hydroxy-1-cyclopropane carboxylic acid, 4-hydroxybutanoic acid, 2-hydroxyhexanoic acid, hydroxylauric acid, 12-hydroxylauric acid, 10-hydroxydecanoic acid, 16-hydroxyhexadecanoic acid, 4-hydroxydecanoic acid, 5-hydroxydecanoic acid, and 4-hydroxy-2, 2-diphenylbutanoic acid as a free acid or salt form in a pharmaceutically or cosmetically acceptable vehicle.
  18. 18. The method of
    claim 17
    wherein said skin conditions and disorders include dry skin, dandruff, keratoses, age spots, wrinkles, warts, acne, oily skin, eczema, psoriasis, inflammatory and pruritic skin, and disturbed keratinization.
  19. 19. An enhanced therapeutic composition effective against skin conditions and disorders comprising an effective amount of at least one member selected from the group consisting of hydroquinone and hydroquinone monoether including monomethyl and monobenzyl ether and an enhancing effective amount of at least one member selected from the group consisting of hydroxycarboxylic acids and related ketocarboxylic acids, and ester, lactone or salt form thereof, in a pharmaceutically acceptable vehicle for topical application to skin of human or animal body.
  20. 20. The composition of
    claim 19
    wherein said skin conditions and disorders include keratoses, age spots, wrinkles, brownish spots, melasma, lentigines and other pigmented skin spots.
  21. 21. The composition of
    claim 19
    wherein said acids and related compounds include glycolic acid, benzilic acid, tropic acid, lactic acid, malic acid, citric acid, isocitric acid, citramalic acid, tartronic acid, tartaric acid, gluconic acid, galactonic acid, alpha hydroxyisobutyric acid, phenyllactic acid, mandelic acid, atrolactic acid, gluconolactone, galactonolactone, ribonic acid, ribonolactone, pantoic acid, pantolactone, pantothenic acid, alpha hydroxybutyric acid, Beta hydroxybutyric acid, quinic acid, pyruvic acid, phenyl pyruvic acid, methyl pyruvate, ethyl pyruvate, ascorbic acid, benzoyl formic acid,. methyl benzoyl formate, and ethyl benzoyl formate.
  22. 22. A method for enhancing therapeutic effects a composition of hydroquinone or its monoether derivative in a pharmaceutically acceptable vehicle comprising admixing therewith an enhancing effective amount of at least one member selected from the group consisting of hydroxycarboxylic acids and related ketocarboxylic acids, and ester, lactone or salt forms thereof.
  23. 23. The method of
    claim 22
    wherein said hydroxyacids and related compounds include glycolic acid, benzilic acid, tropic acid, lactic acid, malic acid, citric acid, isocitric acid, citramalic acid, tartronic acid, tartaric acid, gluconic acid, galactonic acid, alpha hydroxyisobutyric acid, phenyllactic acids mandelic acid, atrolactic acid, gluconolactone, galactonolactone, ribonic acid, ribonolactone, pantoic acid, pantolactone, pantothenic acid, alpha hydroxybutyric acid, beta hydroxybutyric acid, quinic acid, pyruvic acid, phenyl pyruvic acid, methyl pyruvate, ethyl pyruvate, ascorbic acid, benzoyl formic acid, methyl benzoyl formate, ethyl benzoyl formate.
  24. 24. A method for preventing hair loss and/or enhancing hair growth comprising the topical application of a combination composition consisting of minoxidil or dipyridamole and an enhancing effective amount of at least one member selected from the group consisting of hydroxycarboxylic acids and related ketocarboxylic acids, and ester, lactone or salt forms thereof pharmaceutically acceptable vehicle for topical application to skin of human or animal body.
  25. 25. The method of
    claim 24
    wherein said hydroxycarboxylic acid or related compound is a member selected from the group consisted of lactic acid, glycolic acid, glucuronic acid, gluconolactone, gluconic acid, 2-methyl 2-hydroxypropanoic acid, mandelic acid, tropical acid, benzilic acid, malic acid, tartaric acid, citric acid, tartronic acid, pyruvic acid, methyl pyruvate, ethyl pyruvate, saccharic acid, isocitric acid, agaricic acid, citramalic acid, aleuritic acid, mucic acid, galaturonic acid, phenyllactic acid, benzoylformic acid, atrolactic acid, galactonic acid, ascorbic acid, dihydroascorbic acid, pantoyllactone, gulonic acid, gulonolactone, pantoic acid, ribonic acid, ribonolactone, 3-hydroxybutanoic acid, 4-hydroxymandelic acid,-2-hydroxy-3-methylbutanoic acid, 3-hydroxy-4-methoxymandelic acid, 4-hydroxy-3-methoxymandelic acid, 4-chloromandelic acid, 2-hydroxy-4-methylpentanoic acid, 2-hydroxy-2-methylbutanoic acid, 3-(2-hydroxyphenyl) lactic acid, 3-(4-hydroxyphenyl) lactic acid and hexahydromandelic acid.
  26. 26. A therapeutic composition useful in preventing hairloss and/or enhancing hairgrowth comprising a combination composition consisting of an effective amount of minoxidil or dipyridamole and an enhancing effective amount of at least one member selected from the group consisting of hydroxycarboxylic acids and related ketocarboxylic acids, and ester, lactone or salt forms thereof pharmaceutically acceptable vehicle for topical application to skin of human or animal body.
  27. 27. The composition of
    claim 26
    wherein said hydroxycarboxylic acid or related compound is a member selected from the group consisted of lactic acid, glycolic acid, glucuronic acid, gluconolactone, gluconic acid, 2-methyl 2-hydroxypropanoic acid, mandelic acid, tropic acid, benzilic acid, malic acid, tartaric acid, citric acid, tartronic acid, pyruvic acid, methyl pyruvate, ethyl pyruvate, saccharic acid, isocitric acid, agaricic acid, citramalic acid, aleuritic acid, mucic acid, galacturonic acid, phenyllactic acid, benzoylformic acid, atrolactic acid, galactonic acid, ascorbic acid, dihydroascorbic acid, pantoyllactone, gulonic acid, gulonolactone, pantoic acid, ribonic acid, ribonolactone, 3-hydroxybutanoic acid, 4-hydroxymandelic acid, 2-hydroxy-3-methylbutanoic acid, 3-hydroxy-4-methoxymandelic acid, 4-hydroxy-3-methoxymandelic acid, 4-chloromandelic acid, 2-hydroxy-4-methylpentanoic acid, 2-hydroxy-2-methylbutanoic acid, 3-(2-hydroxyphenyl) lactic acid, 3-(4-hydroxyphenyl) lactic acid and hexahydromandelic acid.
  28. 28. A therapeutic composition useful in preventing hairloss and/or enhancing hair growth comprising an effective amount of dipyridamole in a pharmaceutically acceptable vehicle for topical application to skin of human or animal body.
  29. 29. A method for preventing hairloss and/or enhancing hair growth comprising the topical application of a composition consisting of dipyridamole in a pharmaceutically acceptable vehicle for topical application to skin of human or animal body.
  30. 30. A prophylactic and therapeutic composition effective against acne and for oily skin and as skin cleanser comprising an effective amount of benzilic acid in a pharmaceutically acceptable vehicle for topical application to skin of human or animal body.
  31. 31. A method for preventing as well as treating acne or for oily skin as skin cleanser comprising the topical application to involved skin of a composition containing an effective amount of benzilic acid in a pharmaceutically acceptable vehicle for topical application to skin of human or animal body.
  32. 32. A method for preventing as well as treating wrinkles or skin changes associated with aging of skin comprising the topical application to involved skin of a composition containing a therapeutic effective amount of at least one member selected from the group consisted of hydroxycarboxylic acids and related ketocarboxylic acids, and ester, lactone or salt forms thereof.
  33. 33. The method of
    claim 32
    wherein said hydroxycarboxylic acids and related compounds include 2-Hydroxyacetic acid; 2-hydroxypropanoic acid; 2-methyl 2-hydroxypropanoic acid; 2-hydroxybutanoic acid; phenyl 2-hydroxyacetic acid; phenyl 2-methyl 2-hydroxyacetic acid; 3-phenyl 2-hydroxyacetic acid; 2,3-dihydroxypropanoic acid; 2,3,4-trihydroxybutanoic acid, 2,3,4,5-tetrahydroxypentanoic acid, 2,3,4,5,6-pentahydroxyhexanoic acid, 2-hydroxydodecanoic acid, 2,3,4,5,6,7-hexahydroxyheptanoic acid, diphenyl 2-hydroxyacetic acid; 4-hydroxymandelic acid; 4-chloromandelic acid; 3-hydroxybutanoic acid; 4-hydroxybutanoic acid; 2-hydroxyhexanoic acid; 5-hydroxydodecanoic acid, 12-hydroxydodecanoic acid, 10-hydroxydecanoic acid, 16-hydroxyhexadecanoic acid, 2-hydroxy-3-methylbutanoic acid; 2-hydroxy-4-methylpentanoic acid; 3-hydroxy-4-methoxymandelic acid; 4-hydroxy-3-methoxymandelic acid; 2-hydroxy-2-methylbutanoic acid; 3-(2-hydroxyphenyl) lactic acid: 3-(4-hydroxyphenyl) lactic acid; hexahydromandelic acid; 3-hydroxy-3-methylpentanoic acid; 4-hydroxydecanoic acid; 5-hydroxydecanoic acid; aleuritic acid; 2-Hydroxypropanedioic acid; 2-hydroxybutanedioic acid; erythraric acid; threaric acid; arabiraric acid; ribaric acid; xylaric acid; lyxaric acid; glucaric acid; galactaric acid; mannaric acid; gularic acid; allaric acid; altraric acid; idaric acid; talaric acid; 2-hydroxy-2-methylbutanedioic acid;
    Citric acid, isocitric acid, agaricic acid, quinic acid, glucuronic acid, glucuronolactone, galacturonic acid, galacturonolactone, uronic acids, uronolactones, ascorbic acid, dihydroascorbic acid, dihydroxytartaric acid, tropic acid, ribonolactone, gluconolactone, galactonolactone, gulonolactone, mannonolactone, ribonic acid, gluconic acid, citramalic acid;
    Pyruvic acid, hydroxypyruvic acid, hydroxypyruvic acid phosphate, methyl pyruvate, ethyl pyruvate, propyl pyruvate, isopropyl pyruvate; phenyl pyruvic acid, methyl phenyl pyruvate, ethyl phenyl pyruvate, propyl phenyl pyruvate; formyl formic acid, methyl formyl formate, ethyl formyl formate, propyl formyl formate, benzoyl formic acid, methyl benzoyl formate, ethyl benzoyl formate, propyl benzoyl formate, 4-hydroxybenzoyl formic acid, 4-hydroxyphenyl pyruvic acid, 2-hydroxyphenyl pyruvic acid.
  34. 34. A prophylactic and therapeutic compositions comprising an effective amount of at least one member selected from the group consisted of hydroxycarboxylic acids and related ketocarboxylic acids, and ester, lactone or salt forms thereof in a pharmaceutically acceptable vehicle for topical treatment of skin wrinkles or skin changes associated with aging.
  35. 35. The composition of
    claim 34
    wherein said hydroxycarboxylic acids and related compounds include 2-Hydroxyacetic acid; 2-hydroxypropanoic acid; 2-methyl 2-hydroxypropanoic acid; 2-hydroxybutanoic acid; phenyl 2-hydroxyacetic acid; phenyl 2-methyl 2-hydroxyacetic acid; 3-phenyl 2-hydroxyacetic acid; 2,3-dihydroxypropanoic acid; 2,3,4-trihydroxybutanoic acid, 2,3,4,5-tetrahydroxypentanoic acid, 2,3,4,5,6-pentahydroxyhexanoic acid, 2-hydroxydodecanoic acid, 2,3,4,5,6,7-hexahydroxyheptanoic acid, diphenyl 2-hydroxyacetic acid; 4-hydroxymandelic acid; 4-chloromandelic acid; 3-hydroxybutanoic acid; 4-hydroxybutanoic acid; 2-hydroxyhexanoic acid; 5-hydroxydodecanoic acid, 12-hydroxydodecanoic acid, 10-hydroxydecanoic acid, 16-hydroxyhexadecanoic acid, 2-hydroxy-3-methylbutanoic acid; 2-hydroxy-4-methylpentanoic acid; 3-hydroxy-4-methoxymandelic acid; 4-hydroxy-3-methoxymandelic acid; 2-hydroxy-2-methylbutanoic acid; 3-(2-hydroxyphenyl) lactic acid; 3-(4-hydroxyphenyl) lactic acid; hexahydromandelic acid; 3-hydroxy-3-methylpentanoic acid; 4-hydroxydecanoic acid; 5-hydroxydecanoic acid; aleuritic acid; 2-Hydroxypropanedioic acid; 2-hydroxybutanedioic acid; erythraric acid; threaric acid; arabiraric acid; ribaric acid; xylaric acid; lyxaric acid; glucaric acid; galactaric acid; mannaric acid; gularic acid; allaric acid; altraric acid; idaric acid; talaric acid; 2-hydroxy-2-methylbutanedioic acid;
    Citric acid, isocitric acid, agaricic acid, quinic acid, glucuronic acid, glucuronolactone, galacturonic acid, galacturonolactone, uronic acids, uronolactones, ascorbic acid, dihydroascorbic acid, dihydroxytartaric acid, tropic acid, ribonolactone, gluconolactone, galactonolactone, gulonolactone, mannonolactone, ribonic acid, gluconic acid, citramalic acid;
    Pyruvic acid, hydroxypyruvic acid, hydroxypyruvic acid phosphate, their esters; methyl pyruvate, ethyl pyruvate, propyl pyruvate, isopropyl pyruvate; phenyl pyruvic acid, its esters; methyl phenyl pyruvate, ethyl phenyl pyruvate, propyl phenyl pyruvate; formyl formic acid, its esters; methyl formyl formate, ethyl formyl formate, propyl formyl formate; benzoyl formic acid, its esters; methyl benzoyl formate, ethyl benzoyl formate, propyl benzoyl formate; 4-hydroxybenzoyl formic acid, its esters; 4-hydroxyphenyl pyruvic acid, its esters; 2-hydroxyphenyl pyruvic acid and its esters.
US09774882 1986-12-23 2001-02-01 Additives enhancing topical actions of therapeutic agents Abandoned US20010016604A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
US94568086 true 1986-12-23 1986-12-23
US46973890 true 1990-01-19 1990-01-19
US81285891 true 1991-12-23 1991-12-23
US08008223 US5665776A (en) 1986-12-23 1993-01-22 Additives enhancing topical actions of therapeutic agents
US5389677B1 US5389677B1 (en) 1986-12-23 1993-07-12 Method of treating wrinkles using glycalic acid
US08179190 US5470880A (en) 1986-12-23 1994-01-10 Method of using citric acid for the treatment of wrinkles
US08487684 US5691378A (en) 1986-12-23 1995-06-07 Method for treating wrinkles using combinations of alpha hydroxyacids and/or alpha ketoacids
US08926030 US5962526A (en) 1986-12-23 1997-09-09 Pharmaceutical compositions containing hydroxycarboxylic acids and/or ketocarboxylic acids and methods of using same
US09222997 US6051609A (en) 1997-09-09 1998-12-30 Additives enhancing the effect of therapeutic agents
US51036800 true 2000-02-22 2000-02-22
US09774882 US20010016604A1 (en) 1986-12-23 2001-02-01 Additives enhancing topical actions of therapeutic agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09774882 US20010016604A1 (en) 1986-12-23 2001-02-01 Additives enhancing topical actions of therapeutic agents

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US51036800 Continuation 2000-02-22 2000-02-22

Publications (1)

Publication Number Publication Date
US20010016604A1 true true US20010016604A1 (en) 2001-08-23

Family

ID=25483418

Family Applications (3)

Application Number Title Priority Date Filing Date
US08008223 Expired - Fee Related US5665776A (en) 1986-12-23 1993-01-22 Additives enhancing topical actions of therapeutic agents
US09774882 Abandoned US20010016604A1 (en) 1986-12-23 2001-02-01 Additives enhancing topical actions of therapeutic agents
US10071345 Abandoned US20030017130A1 (en) 1986-12-23 2002-02-08 Additives enhancing topical applications of therapeutic agents

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US08008223 Expired - Fee Related US5665776A (en) 1986-12-23 1993-01-22 Additives enhancing topical actions of therapeutic agents

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10071345 Abandoned US20030017130A1 (en) 1986-12-23 2002-02-08 Additives enhancing topical applications of therapeutic agents

Country Status (6)

Country Link
US (3) US5665776A (en)
EP (3) EP0599819B1 (en)
JP (1) JP2533339B2 (en)
CA (1) CA1324077C (en)
DE (3) DE3752045T2 (en)
ES (2) ES2103506T3 (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020098210A1 (en) * 1997-06-23 2002-07-25 Hahn Gary S. Formulations and methods for reducing skin irritation
US20030124202A1 (en) * 1994-12-21 2003-07-03 Hahn Gary S. Formulations and methods for reducing skin irritation
EP1448205A2 (en) * 2001-10-05 2004-08-25 Combinatorx, Incorporated Combinations for the treatment of immunoinflammatory disorders
US20050095261A1 (en) * 2003-11-03 2005-05-05 Popp Karl F. Antimicrobial topical compositions for treatment of rosacea
US6949249B2 (en) 2000-05-08 2005-09-27 Pfizer Inc. Skin protectant spray compositions
US20060093675A1 (en) * 2004-10-29 2006-05-04 Mathew Ebmeier Intravaginal treatment of vaginal infections with metronidazole compositions
US20060200174A1 (en) * 2001-05-08 2006-09-07 Stough Dowling B Wart removal method and device
US20070010502A1 (en) * 2003-10-15 2007-01-11 Combinatorx Inc. Methods and reagents for the treatment of immunoinflammatory disorders
US20070071705A1 (en) * 2005-09-29 2007-03-29 De Oliveira Monica A M Topical anti-microbial compositions
US20080003213A1 (en) * 2006-05-22 2008-01-03 Jan Lessem Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein, interleukin-6, or interferon-gamma levels
US7404967B2 (en) * 1994-12-21 2008-07-29 Cosmederm, Inc. Topical product formulations containing strontium for reducing skin irritation
US20090075955A1 (en) * 2007-09-19 2009-03-19 Combinatorx, Inc. Therapeutic regimens for the treatment of immunoinflammatory disorders
US20100125104A1 (en) * 2008-11-20 2010-05-20 Chata Biosystems, Inc. Alpha-Keto Peracids and Methods For Producing and Using the Same
US20100261792A1 (en) * 2008-11-20 2010-10-14 Chata Biosystems, Inc. Alpha-Keto Alkylperacids and Methods For Producing and Using the Same
US20110189293A1 (en) * 2007-12-17 2011-08-04 CombinatoRx, Incoporated Therapeutic regimens for the treatment of immunoinflammatory disorders
US8013017B2 (en) 2001-05-31 2011-09-06 Upsher-Smith Laboratories, Inc. Dermatological compositions and methods
US9044527B2 (en) 2011-02-17 2015-06-02 Chd Bioscience, Inc. Wound care products with peracid compositions
KR20150085970A (en) * 2014-01-17 2015-07-27 주식회사 엘지생활건강 Cosmetic or pharmaceutical composition for promoting hair growth containing Hydroxydecanoic acid
US9283202B2 (en) 2012-10-18 2016-03-15 Chd Bioscience, Inc. Stable peracid-containing compositions
US9545368B2 (en) 2013-08-09 2017-01-17 The Chemours Company Fc, Llc Skin care compositions having cyclic diesters and methods thereof
US9578879B1 (en) 2014-02-07 2017-02-28 Gojo Industries, Inc. Compositions and methods having improved efficacy against spores and other organisms

Families Citing this family (199)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714482A (en) * 1985-07-18 1998-02-03 Proctor; Peter H. Topical spin labels and method
US5470876A (en) * 1985-07-18 1995-11-28 Proctor; Peter H. Topical sod for treating hair loss
US5472687A (en) * 1985-07-18 1995-12-05 Proctor; Peter H. Topical pyridine N-oxides
US5728714A (en) * 1985-07-18 1998-03-17 Proctor; Peter H. Method for treating hair loss using tempo
US5716947A (en) * 1985-07-18 1998-02-10 Proctor; Peter H. Topical doxyl composition and method
US5714510A (en) * 1985-07-18 1998-02-03 Proctor; Peter H. Topical proxyl composition and method
US6150405A (en) * 1985-07-18 2000-11-21 Proctor; Peter H. Hair loss treatment with ascorbates
US5352442A (en) * 1985-07-18 1994-10-04 Proctor Peter H Topical tempo
US5723502A (en) * 1985-07-18 1998-03-03 Proctor; Peter H. Topical spin trap composition and method
US6384079B1 (en) 1986-12-23 2002-05-07 Tristrata Technology, Incorporated Compositions comprising 2-hydroxycarboxylic acids and related compounds, and methods for alleviating signs of dermatological aging
US5389677B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of treating wrinkles using glycalic acid
US5834510A (en) * 1986-12-23 1998-11-10 Tristrata Technology, Inc. Compositions comprising 2-hydroxycarboxylic acids and related compounds, and methods for alleviating signs of dermatological aging
US5942250A (en) * 1986-12-23 1999-08-24 Tristrata Technology, Inc. Compositions and methods for enhancing the topical effects of sunscreen agents
CA1324077C (en) * 1986-12-23 1993-11-09 Scott Eugene J. Van Additives enhancing topical actions of therapeutic agents
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
US5686489A (en) * 1986-12-23 1997-11-11 Tristrata Technology, Inc. Alpha hydroxyacid esters for skin aging
US4885282A (en) * 1987-07-02 1989-12-05 Thornfeldt Carl R Treatment of hyperhidrosis, ichthyosis and wrinkling
US4885275A (en) * 1987-10-15 1989-12-05 Eli Lilly And Company Vancomycin-HCL solutions and the lyophilization thereof
EP0327263B1 (en) * 1988-01-29 1994-09-07 PROCTOR, Peter H. Hair growth stimulation with nitroxide and other radicals
FR2629346B1 (en) * 1988-04-01 1991-03-29 Egyt Gyogyszervegyeszeti Gyar Compositions synergistically active veterinary and method for making
JPH02104531A (en) * 1988-10-14 1990-04-17 Toyo Jozo Co Ltd Physiologically active peptide composition for nasal application
US5004754A (en) * 1989-06-05 1991-04-02 Universite Laval Biofungicidal composition
JP2593714B2 (en) * 1989-09-20 1997-03-26 三省製薬 株式会社 Skin-whitening agent
GB8923667D0 (en) * 1989-10-20 1989-12-06 Unilever Plc Hair treatment composition
GB9003201D0 (en) * 1990-02-13 1990-04-11 Unilever Plc Cosmetic composition
US5028418A (en) * 1990-03-19 1991-07-02 Bristol-Myers Squibb Company Antiperspirant process and imdazole containing compositions utilizable therein
JP2564690B2 (en) * 1990-06-14 1996-12-18 三省製薬 株式会社 Melanin formation inhibitory preparation for external use
GB9026664D0 (en) * 1990-12-07 1991-01-23 Unilever Plc Cosmetic composition
US5254343A (en) * 1991-03-19 1993-10-19 Bristol-Myers Squibb Company Reduction of cutaneous atrophy
DE69228622D1 (en) * 1991-04-10 1999-04-22 Eugene J Van Dr Scott Use of 2-hydroxycarboxylic acid or derivatives thereof containing composition for the relief of bills nail changes
FR2678830B1 (en) * 1991-07-08 1995-03-17 Sederma Sa
EP0614353A1 (en) * 1991-11-25 1994-09-14 Richardson-Vicks, Inc. Compositions for regulating skin wrinkles and/or skin atrophy
CA2122271C (en) * 1991-11-25 1998-06-23 Roy L. Blank Use of salicylic acid for regulating skin wrinkles and/or skin atrophy
US5780459A (en) * 1991-11-25 1998-07-14 The Procter & Gamble Company Compositions for regulating skin wrinkles and or skin atrophy
GB9209238D0 (en) * 1992-04-29 1992-06-17 Unilever Plc Cosmetic conditioner
US5686086A (en) * 1992-07-13 1997-11-11 Shiseido Co., Ltd. External skin treatment composition
DE69332818D1 (en) * 1992-07-13 2003-05-08 Shiseido Co Ltd Composition for dermatological preparation
US5962000A (en) * 1992-07-13 1999-10-05 Shiseido Company, Ltd. External skin treatment composition
ES2083254T3 (en) * 1992-08-06 1996-04-01 Beta Pharm Co Compositions for topical administration of spironolactone.
DE69231968D1 (en) * 1992-09-11 2001-08-30 Nicholas V Perricone Treatment of erythema caused by ultraviolet radiation
WO1994017776A1 (en) * 1993-02-09 1994-08-18 Tulsa Forte Pharmacy Enterprises, Inc. A method for stimulating hair growth with cationic derivatives of minoxidil using therapeutic iontophoresis
EP0703775A4 (en) * 1993-06-01 1997-02-26 Dermatology Home Prod Inc Skin treatment method utilizing a composition and a pad
US5505948A (en) * 1993-06-01 1996-04-09 Dermatology Home Products, Inc. Home skin peel composition for producing healthy and attractive skin
WO1995005156A1 (en) * 1993-08-17 1995-02-23 Schering-Plough Healthcare Products, Inc. Compositions for treating corns, calluses and warts
DE4329379C1 (en) * 1993-09-01 1995-02-16 Beiersdorf Ag Against blemished skin, mild forms of acne effective preparations with a content of wool wax acids
CN1100532C (en) * 1993-11-12 2003-02-05 普罗克特和甘保尔公司 Desquamation copositions contaiig salicylic acid and zwitterionic compounds
FR2718022B1 (en) 1994-04-01 1996-04-26 Roussel Uclaf cosmetic or dermatological compositions and their preparation.
US5869069A (en) * 1994-07-22 1999-02-09 Coletica Lipophilic hydroxylated acid, its use in cosmetics and pharmacy, and its process of preparation
WO1996008233A1 (en) * 1994-09-14 1996-03-21 Kuyus-Stiftung Cosmetic process
FR2725898B1 (en) * 1994-10-24 1996-12-13 Oreal Product for topical application containing a lipase and a precursor hydroxyacid
US5540920A (en) * 1994-11-22 1996-07-30 Olin Corporation Synergistic biocide composition containing pyrithione plus an additive
WO1997000676A1 (en) * 1995-06-21 1997-01-09 Oy Extracta Ltd. Antimicrobial and anti-inflammatory compounds
FR2738743B1 (en) * 1995-09-19 1997-11-14 Oreal Use of ascorbic acid as active for the treatment of seborrhea in a cosmetic and / or dermatological
DE19608775A1 (en) * 1996-03-07 1997-09-11 Beiersdorf Ag Hair cosmetic preparations on the basis of phytosterols and alpha-hydroxycarboxylic acids
US6086789A (en) * 1996-03-18 2000-07-11 Case Western Reserve University Medical uses of pyruvates
US5753702A (en) * 1996-05-22 1998-05-19 University Of Vermont Arachidonic acid metabolite, 16-hete
KR100521787B1 (en) * 1997-01-09 2005-10-14 콘렉스 파마슈티칼 코포레이션 Composition for enhancing skin or hair
US8106094B2 (en) 1998-07-06 2012-01-31 Johnson & Johnson Consumer Companies, Inc. Compositions and methods for treating skin conditions
US8039026B1 (en) 1997-07-28 2011-10-18 Johnson & Johnson Consumer Companies, Inc Methods for treating skin pigmentation
US8093293B2 (en) 1998-07-06 2012-01-10 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin conditions
GB9723669D0 (en) * 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
WO1999029640A3 (en) * 1997-12-05 2000-01-13 Vitukudi Narayanaiyenga Balaji Compositions and methods for modulating the activity of fibroblast growth factor
EP1035845A1 (en) 1997-12-14 2000-09-20 Dorit Arad Modulators of cysteine protease
US6036963A (en) * 1998-02-26 2000-03-14 Chesebrough-Ponds's Usa Co., Division Of Conopco, Inc. Gluconolactones and glucarolactones as anti-irritants in cosmetic compositions
ES2268856T3 (en) * 1998-04-22 2007-03-16 Connetics Australia Pty Limited pharmaceutical composition.
FR2779053B1 (en) * 1998-05-28 2000-07-13 Oreal Derivative Association of pyrimidine derivatives and azoles to induce and / or stimulate hair growth and / or reducing hair loss
DE19826499A1 (en) * 1998-06-13 1999-12-16 Beiersdorf Ag Use of lactone, thiolactone and/or dithiolactone derivatives
EP1143950B1 (en) * 1998-09-10 2005-03-09 BioEqual AG Topical application products against onychomycoses
FR2783714B1 (en) * 1998-09-29 2002-07-19 Led Evolution Dermatolog Composition based on hydroquinone and metabisulfite used topically for the depigmentation of the skin
US6521237B2 (en) 1998-11-12 2003-02-18 Johnson & Johnson Consumer Companies, Inc. Skin care composition
US7396526B1 (en) 1998-11-12 2008-07-08 Johnson & Johnson Consumer Companies, Inc. Skin care composition
US6159485A (en) 1999-01-08 2000-12-12 Yugenic Limited Partnership N-acetyl aldosamines, n-acetylamino acids and related n-acetyl compounds and their topical use
US6808716B2 (en) 1999-01-08 2004-10-26 Ruey J. Yu N-acetylamino acids, related N-acetyl compounds and their topical use
US7816402B2 (en) 1999-03-19 2010-10-19 Bioderm, Inc. Compositions and methods for the treatment of skin
US6217914B1 (en) 1999-03-19 2001-04-17 Bioderm, Inc. Ascorbic acid composition and method for treatment of aging or damaged skin
FR2791260B1 (en) * 1999-03-26 2003-06-06 Dior Christian Parfums Cosmetic or dermatological compositions containing at least one substance destinee to increase the functionality and / or expression of the CD44 membrane receptors of skin cells
US20030003170A1 (en) 2000-06-02 2003-01-02 Theresa Callaghan Method for the topical treatment and prevention of inflammatory disorders and related conditions using extracts of feverfew (Tanacetum parthenium)
FR2795325A1 (en) * 1999-06-24 2000-12-29 B F B Topical compositions contain erythromycin and a dicarboxylic acid, for the treatment of acne
US7452545B2 (en) 2001-11-13 2008-11-18 Yu Ruey J Oligosaccharide aldonic acids and their topical use
US6335023B1 (en) 1999-06-30 2002-01-01 Ruey J. Yu Oligosaccharide aldonic acids and their topical use
FR2795952B1 (en) * 1999-07-08 2003-05-30 Oreal dandruff treatment composition of the hair and scalp, dandruff is based assets and hydroxy
US7985404B1 (en) 1999-07-27 2011-07-26 Johnson & Johnson Consumer Companies, Inc. Reducing hair growth, hair follicle and hair shaft size and hair pigmentation
US6287582B1 (en) * 1999-08-24 2001-09-11 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Towelette product
DE10013578A1 (en) * 2000-03-18 2001-09-20 Haarmann & Reimer Gmbh Use of 3,4-dihydroxymandelic acid and/or stereoisomers as antioxidants and/or radical scavengers in protecting mammalian skin, cosmetic or pharmaceutical preparations, foodstuffs, lacquers and polymers
JP4074043B2 (en) 2000-03-27 2008-04-09 株式会社資生堂 Skin basement membrane formation promoting agent, artificial skin formation promoting agent and a process for producing an artificial skin
US6630175B1 (en) 2000-06-29 2003-10-07 Johnson & Johnson Consumer Companies, Inc. Method of reducing eye irritation
US6372791B1 (en) 2000-06-29 2002-04-16 Johnson & Johnson Consumer Companies, Inc. Method of promoting skin cell metabolism
US6432424B1 (en) 2000-06-29 2002-08-13 Johnson & Johnson Consumer Companies, Inc. Cosmetic compositions containing creatine, carnitine, and/or pyruvic acid
US6649176B1 (en) 2000-06-29 2003-11-18 Johnson & Johnson Consumer Companies, Inc. Compositions containing mineral water
US20020119174A1 (en) * 2000-07-26 2002-08-29 Gardlik John Michael Compositions useful for regulating hair growth containing metal complexes of oxidized carbohydrates
US20020035070A1 (en) * 2000-07-26 2002-03-21 The Procter & Gamble Company Method of regulating hair growth using metal complexes of oxidized carbohydrates
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
DE60137243D1 (en) 2000-09-27 2009-02-12 Thia Medica As Fatty acid analog for the treatment of proliferative skin disorders
US20040213754A1 (en) * 2000-10-02 2004-10-28 Cole Curtis A. Method for cleansing sensitive skin using an alkanolamine
KR20020027198A (en) * 2000-10-02 2002-04-13 차알스 제이. 메츠 Method for reduction of inflammation and erythema
US8431550B2 (en) 2000-10-27 2013-04-30 Johnson & Johnson Consumer Companies, Inc. Topical anti-cancer compositions and methods of use thereof
US6482446B2 (en) 2000-12-01 2002-11-19 Neutrogena Corporation Astringent composition and method of use
JP2002212060A (en) * 2001-01-18 2002-07-31 Tsumura & Co Detergent composition
US7192615B2 (en) 2001-02-28 2007-03-20 J&J Consumer Companies, Inc. Compositions containing legume products
US6555143B2 (en) 2001-02-28 2003-04-29 Johnson & Johnson Consumer Products, Inc. Legume products
ES2387717T3 (en) 2001-02-28 2012-09-28 Johnson & Johnson Consumer Companies, Inc. Compositions containing legume products
WO2002074280A1 (en) 2001-03-16 2002-09-26 Johnson & Johnson Consumer Companies, Inc. Composition containing feverfew extract and use thereof
WO2002081020A3 (en) * 2001-04-04 2003-01-09 Critical Therapeutics Inc Method for preventing acute renal failure
US6585742B2 (en) 2001-05-08 2003-07-01 Dowling B. Stough Wart removal method and device
US7214655B2 (en) 2001-05-21 2007-05-08 Johnson & Johnson Consumer Companies, Inc. Peptides and the use thereof in darkening the skin
US6797697B2 (en) 2001-05-21 2004-09-28 Johnson & Johnson Consumer Companies, Inc. Composition containing a peptide and a pigment and the use thereof in darkening the skin
US7081442B2 (en) 2001-05-21 2006-07-25 Johnson & Johnson Consumer Companies, Inc. Composition containing a peptide and a pigment and the use thereof in darkening the skin
JP4643862B2 (en) * 2001-07-02 2011-03-02 日清オイリオグループ株式会社 Film formers, skin external preparation and a cosmetic composition
US20050238730A1 (en) * 2001-11-21 2005-10-27 Agnes Le Fur Compositions comprising an ethanolamine derivative and organic metal salts
US6824786B2 (en) * 2001-11-27 2004-11-30 Ruey J. Yu Compositions comprising phenyl-glycine derivatives
US7147873B2 (en) 2002-01-16 2006-12-12 3M Innovative Properties Company Antiseptic compositions and methods
US6838078B2 (en) 2002-01-16 2005-01-04 3M Innovative Properties Company Film-forming compositions and methods
JP2005527592A (en) * 2002-04-17 2005-09-15 クリティカル セラピューティクス,インコーポレイテッド α- keto alkanoic acid or - ester or - a method of treating ileus using amide
US6846847B2 (en) * 2002-07-24 2005-01-25 James G. Holwerda Biocidal agents and methods of use
US7008620B2 (en) 2002-09-30 2006-03-07 Johnson & Johnson Consumer Companies, Inc. Depilatory compositions and articles and the use thereof
US7842723B2 (en) * 2002-10-04 2010-11-30 Bioderm Research Ascorbic acid—natural sugar lactone esters for comprehensive skin and scalp care
US6926886B2 (en) 2002-10-31 2005-08-09 Johnson & Johnson Consumer Companies, Inc. Compositions for darkening the skin and/or hair
DE10260955A1 (en) * 2002-12-20 2004-07-08 Henkel Kgaa Use of steroid sulfatase inhibitors for the reduction of hair loss
US8343519B2 (en) * 2003-02-19 2013-01-01 L'oreal S.A. Chemical enhancer and method
US20040161392A1 (en) * 2003-02-19 2004-08-19 L'oreal S.A. Skin peeling composition and method
US20040214215A1 (en) * 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
FR2852828A1 (en) * 2003-03-25 2004-10-01 Oreal materials processing keratin composition comprising a hydroxycarboxylic acid and a protecting or conditioning agent
US20040220259A1 (en) * 2003-04-04 2004-11-04 Yu Ruey J. Topical treatment of dermatological disorders associated with reactive or dilated blood vessels
US7326717B2 (en) 2003-05-06 2008-02-05 L'oreal Pyrimidine n-oxide compounds for stimulating the growth of keratin fibers and/or reducing loss thereof
US20050058673A1 (en) 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
WO2005023023A1 (en) 2003-09-09 2005-03-17 3M Innovative Properties Company Concentrated antimicrobial compositions and methods
EP1662873B1 (en) * 2003-09-09 2016-01-13 3M Innovative Properties Company Antimicrobial compositions and methods
DE10355715A1 (en) * 2003-11-26 2005-06-16 Beiersdorf Ag Active compound combinations creatine and / or creatine derivatives and / or creatinine and / or Kreatininderivaten and an effective amount of retinoids, especially retinol and retinyl palmitate, and formulations comprising such active compound combinations comprising
WO2005079143A3 (en) * 2004-02-19 2006-03-09 Graham William Burton Topical formulations for the treatment of skin conditions
US7320956B2 (en) * 2004-04-01 2008-01-22 3M Innovative Properties Company Aqueous cleaning/treatment composition for fibrous substrates
US9028852B2 (en) 2004-09-07 2015-05-12 3M Innovative Properties Company Cationic antiseptic compositions and methods of use
US20060051384A1 (en) * 2004-09-07 2006-03-09 3M Innovative Properties Company Antiseptic compositions and methods of use
US8198326B2 (en) 2004-09-07 2012-06-12 3M Innovative Properties Company Phenolic antiseptic compositions and methods of use
CA2548532C (en) 2004-09-27 2014-12-02 Rijk Jan De Methods and compositions for treatment of water
EP1806982B1 (en) 2004-09-28 2018-09-19 Avivagen Inc. Compositions and methods for promoting weight gain and feed conversion
US7887824B2 (en) 2004-11-30 2011-02-15 L'oreal Sulfamide derivatives and cosmetic use thereof
EP1676562B2 (en) * 2004-12-16 2016-03-02 Kao Germany GmbH Composition for the hair containing uv filters
US20060205838A1 (en) * 2005-03-10 2006-09-14 Velamakanni Bhaskar V Hardenable antimicrobial dental compositions and methods
EP2497459A1 (en) 2005-03-10 2012-09-12 3M Innovative Properties Co. Methods of reducing microbial contamination
US20060204558A1 (en) * 2005-03-10 2006-09-14 Kantner Steven S Antimicrobial pet wipes and methods
US20060204452A1 (en) * 2005-03-10 2006-09-14 Velamakanni Bhaskar V Antimicrobial film-forming dental compositions and methods
US20060229364A1 (en) * 2005-03-10 2006-10-12 3M Innovative Properties Company Antiviral compositions and methods of use
CN101137357B (en) 2005-03-10 2012-07-04 3M创新有限公司 Antimicrobial compositions comprising esters of hydroxycarboxylic acids
US8476319B2 (en) 2005-03-10 2013-07-02 3M Innovative Properties Company Methods of treating ear infections
WO2006108682A3 (en) * 2005-04-15 2007-03-08 Biomac Privatinstitut Fuer Med Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use as anti-fungal agents
US20060246020A1 (en) 2005-04-29 2006-11-02 Cole Curtis A Topical composition detection
US7919483B2 (en) * 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne
US8722650B1 (en) 2005-06-24 2014-05-13 Medicis Pharmaceutical Corporation Extended-release minocycline dosage forms
US7381707B2 (en) 2005-06-30 2008-06-03 Johnson & Johnson Consumer Companies, Inc. Treatment of dry eye
EP1764081A1 (en) 2005-08-29 2007-03-21 Johnson & Johnson Consumer France SAS Sunscreen composition comprising a dibenzoylmethane, an aminohydroxybenzophenone, a triazine and a triazole as UV filters
US8758838B2 (en) 2005-08-31 2014-06-24 Johnson & Johnson Consumer Companies, Inc. Anti-inflammatory compositions and methods of use
US8697152B2 (en) 2005-08-31 2014-04-15 Johnson & Johnson Consumer Companies, Inc. Anti-inflammatory compositions and personal care compositions comprising olive leaf (Olea europea) extract
JP2009510087A (en) * 2005-09-30 2009-03-12 オーエムピー インコーポレーテッド Stable ascorbic acid composition
US7709014B2 (en) * 2005-10-17 2010-05-04 Yu Ruey J Hydroxy-oligocarboxylic esters: effects on nerve and use for cutaneous and mucocutaneous organs or sites
CN101340916A (en) * 2005-12-22 2009-01-07 兴和株式会社 Preparation for external use having improved temporal stability of steroid
US20070148104A1 (en) * 2005-12-23 2007-06-28 Goettert Edward J Animal chew articles
US20070269534A1 (en) * 2006-02-02 2007-11-22 Ramirez Jose E Methods of treating skin to enhance therapeutic treatment thereof
US20070178058A1 (en) * 2006-02-02 2007-08-02 Ramirez Jose E Methods of using stable ascorbic acid compositions
WO2007104474A1 (en) * 2006-03-10 2007-09-20 Novartis Ag Antifungal compositions comprising (1) a salt of terbinafine with malic acid and (2) malic acid
US7723387B2 (en) * 2006-06-28 2010-05-25 Polymer Surfaces Group, Llc Self-neutralizing acid peel for dermatologic use
US20080075793A1 (en) * 2006-09-21 2008-03-27 Dunshee Wayne K Antiviral compositions and methods of use
CN101489379B (en) 2006-10-27 2014-06-04 3M创新有限公司 Antimicrobial compositions
WO2008117117A3 (en) * 2006-10-27 2009-01-08 Giuseppe Trigiante Compositions and method for hair loss prevention
US20080200890A1 (en) * 2006-12-11 2008-08-21 3M Innovative Properties Company Antimicrobial disposable absorbent articles
US9555167B2 (en) * 2006-12-11 2017-01-31 3M Innovative Properties Company Biocompatible antimicrobial compositions
US20080241235A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US20080241197A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline dosage forms for the treatment of acne
US20080242642A1 (en) 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US8252776B2 (en) 2007-04-02 2012-08-28 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7544373B2 (en) * 2007-04-02 2009-06-09 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7541347B2 (en) * 2007-04-02 2009-06-02 Medicis Pharmaceutical Coropration Minocycline oral dosage forms for the treatment of acne
JP5612476B2 (en) * 2007-11-26 2014-10-22 スリーエム イノベイティブ プロパティズ カンパニー Method of forming microporous and antimicrobial articles
WO2009088894A3 (en) 2007-12-31 2010-07-29 3M Innovative Properties Company Antimicrobial compositions
CA2711663C (en) * 2007-12-31 2017-01-10 3M Innovative Properties Company Liquid antiseptic compositions containing iodine and a sugar and/or sugar alcohol
FR2929118B1 (en) 2008-03-28 2010-05-07 Oreal Using the combination of madecassoside and / or terminoloside and of arginine for inducing and / or stimulating the growth of these human keratin fibers and / or slow down hair loss
FR2929117B1 (en) 2008-03-28 2010-05-07 Oreal Use of the combination of 2,4-diaminopyrimidine 3-n-oxide and madecassosside and / or terminoloside for inducing and / or stimulating the growth of these human keratin fibers and / or slow down hair loss
EP2140859A1 (en) 2008-06-30 2010-01-06 Johnson & Johnson Consumer Companies, Inc. Compositions comprising an ultraviolet radiation-absorbing polymer
US8003132B2 (en) 2008-06-30 2011-08-23 Johnson & Johnson Consumer Companies, Inc. Compositions comprising an ultraviolet radiation-absorbing polymer
WO2010017310A1 (en) 2008-08-06 2010-02-11 Medicis Pharmaceutical Corporation Method for the treatment of acne and certain dosage forms thereof
US7704935B1 (en) * 2009-01-06 2010-04-27 Becton, Dickinson And Company Chlorhexidine acetate antiseptic cleaning agent
WO2010099182A1 (en) * 2009-02-25 2010-09-02 Board Of Regents Of The University Of Nebraska Activated creatinine and precursors as antibacterial agents, compositions and products containing such agents and uses thereof
FR2949052B1 (en) 2009-08-13 2015-03-27 Oreal Process for cosmetic treatment of the scalp.
US8470880B2 (en) * 2009-12-15 2013-06-25 Mcneil-Ppc, Inc. Methods of reducing hair loss and/or facilitating hair growth and/or regrowth
US8470833B2 (en) * 2009-12-15 2013-06-25 Mcneil-Ppc, Inc. Hair growth and/or regrowth compositions
WO2011076721A1 (en) 2009-12-22 2011-06-30 Deutsches Krebsforschungszentrum Fluoroquinolones for the treatment and/or prophylaxis of inflammatory diseases
US8475774B2 (en) 2010-02-08 2013-07-02 Johnson & Johnson Consumer Companies, Inc. Sunscreen compositions comprising an ultraviolet radiation-absorbing polymer
US8808722B2 (en) 2010-06-29 2014-08-19 3M Innovative Properties Company Stable antiseptic compositions and methods
JP5132740B2 (en) * 2010-09-09 2013-01-30 大洋香料株式会社 Antibacterial agents
US20120070480A1 (en) 2010-09-17 2012-03-22 3M Innovative Properties Company Antimicrobial disposable absorbent articles
US20130165880A1 (en) 2010-09-17 2013-06-27 David T. Amos Antimicrobial disposable absorbent articles
WO2012177986A3 (en) 2011-06-22 2013-03-14 Vyome Biosciences Conjugate-based antifungal and antibacterial prodrugs
US9561241B1 (en) 2011-06-28 2017-02-07 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for minocycline
JP5947527B2 (en) * 2011-11-28 2016-07-06 互応化学工業株式会社 Method of manufacturing a cosmetic composition
FR2983076B1 (en) * 2011-11-28 2014-08-08 Fabre Pierre Dermo Cosmetique A topical composition comprising a combination of at least one blue-green algae extracted with at least one alpha hydroxy acid or a salt thereof
EP3145514A4 (en) * 2014-05-23 2018-06-20 Paz Garcia, Juan Formulation for regeneration of bone, cartilage, teeth, and periodontium and treatment of tumors and cysts
US20170282516A1 (en) * 2014-10-16 2017-10-05 Mitsubishi Rayon Co., Ltd. Resin composition and compression-molded article of same
US20160366879A1 (en) 2015-06-22 2016-12-22 Infection Containment Company, LLC Topical antiseptic system
EP3284462A1 (en) * 2016-08-17 2018-02-21 Cosmederm Bioscience Inc. Strontium based compositions and formulations for pain, pruritus, and inflammation
KR101890854B1 (en) * 2016-08-04 2018-08-22 주식회사 엘지생활건강 Cosmetic composition for removing skin keratin having superior moisturizing effect

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1772975A (en) * 1925-06-20 1930-08-12 Firm C H Boehringer Sohn Chem Process for the production of antiseptic agents
US2118566A (en) * 1935-08-29 1938-05-24 Miles Gilbert De Wayne Buffered cosmetic
US3227616A (en) * 1961-07-03 1966-01-04 Warner Lambert Pharmaceutical Emulsions of cactus plant extract
FR1439834A (en) * 1963-12-07 1966-05-27 New use in cosmetology of a cellular activator
US3689668A (en) * 1967-10-18 1972-09-05 Emile Leon Piette Method of alleviating wrinkles on skin
US3666863A (en) * 1968-03-06 1972-05-30 Medisan Ab Skin-treating composition and vehicle for skin-treating agents
GB1388836A (en) * 1971-06-01 1975-03-26 Medisan Ab Cosmetic compositions
JPS4898044A (en) * 1972-03-30 1973-12-13
JPS5010381B2 (en) * 1972-04-26 1975-04-21
JPS5025741A (en) * 1973-07-17 1975-03-18
US3984566A (en) * 1974-02-25 1976-10-05 Scott Eugene J Van Method of alleviating the symptoms of dandruff
US3879537A (en) * 1973-09-04 1975-04-22 Scott Eugene J Van Treatment of ichthyosiform dermatoses
US3988470A (en) * 1974-02-25 1976-10-26 Scott Eugene J Van Treatment of palmar and plant disturbed keratosis
US3991184A (en) * 1973-10-05 1976-11-09 Martin Kludas Agent for the care of skin
US3867528A (en) * 1973-10-11 1975-02-18 American Cyanamid Co Steroidal topical cream base
US4294852A (en) * 1973-11-01 1981-10-13 Johnson & Johnson Skin treating compositions
DE2517413A1 (en) * 1974-05-02 1975-11-13 Draco Ab Dermatological agents contg. zinc salts or complexes - for treating e.g. acne or seborrhoea
DE2421638A1 (en) * 1974-05-04 1975-11-20 Henkel & Cie Gmbh Skin care and skin protection products with a content of skin-humectant agents
US4197316A (en) * 1975-07-23 1980-04-08 Scott Eugene J Van Treatment of dry skin
US4380549A (en) * 1975-07-23 1983-04-19 Scott Eugene J Van Topical treatment of dry skin
US4021572A (en) * 1975-07-23 1977-05-03 Scott Eugene J Van Prophylactic and therapeutic treatment of acne vulgaris utilizing lactamides and quaternary ammonium lactates
US4363815A (en) * 1975-07-23 1982-12-14 Yu Ruey J Alpha hydroxyacids, alpha ketoacids and their use in treating skin conditions
BE858404A (en) * 1976-09-07 1978-03-06 Scott Eugene J Van Treatment of said dermatological condition "dry skin"
US4053630A (en) * 1976-07-07 1977-10-11 Yu Ruey J Treatment of body odor and disturbed keratinization
EP0007785B1 (en) * 1978-07-24 1982-04-21 Unilever Plc Skin treatment compositions, process for their preparation and applicator containing these compositions
JPS5535008A (en) * 1978-09-04 1980-03-11 Jiyujiyu Keshohin Kk Cosmetic
JPS5540632A (en) * 1978-09-16 1980-03-22 Nippon Solid Co Ltd Cosmetic pack
US4234599A (en) * 1978-10-04 1980-11-18 Scott Eugene J Van Treatment of skin keratoses with α-hydroxy acids and related compounds
JPS55145607A (en) * 1979-04-28 1980-11-13 Lion Corp Aloin-containing composition
JPS5643443B2 (en) * 1979-05-18 1981-10-13
US4285973A (en) * 1979-07-20 1981-08-25 Alberto-Culver Company Liquid composition for application to the skin
US4246261A (en) * 1979-08-09 1981-01-20 Scott Eugene J Van Additives enhancing topical corticosteroid action
US4287214A (en) * 1979-09-24 1981-09-01 Scott Eugene J Van Dithranol compositions stabilized with alpha hydroxyacids
US4406896A (en) * 1979-12-20 1983-09-27 Merck & Co., Inc. Adjuvants for rectal delivery of drug substances
US4278684A (en) * 1980-06-17 1981-07-14 Janssen Pharmaceutica N.V. Non-toxic anthelminthic pour-on composition
JPH0212925B2 (en) * 1980-09-05 1990-03-30 Sogo Yatsuko Kk
CA1184492A (en) * 1981-01-14 1985-03-26 Masataka Morishita Preparation having excellent absorption property
JPH0468289B2 (en) * 1981-03-06 1992-11-02 Toyo Jozo Kk
JPS57146723A (en) * 1981-03-06 1982-09-10 Toyo Jozo Co Ltd Pharmaceutical preparation having improved absorption
DE3276743D1 (en) * 1981-05-14 1987-08-20 Takeda Chemical Industries Ltd Pharmaceutical preparations containing trh or its analogue
JPH0330566B2 (en) * 1981-07-03 1991-04-30
JPS63405B2 (en) * 1981-12-26 1988-01-07 Lion Corp
US4507319A (en) * 1982-02-02 1985-03-26 Lever Brothers Company Skin treatment composition
US4518789A (en) 1982-06-30 1985-05-21 Yu Ruey J Phenyl alpha-acyloxyacetamide derivatives and their therapeutic use
JPH0314283B2 (en) * 1982-07-16 1991-02-26 Lion Corp
JPS5913716A (en) * 1982-07-16 1984-01-24 Lion Corp Composition for external use
JPS5915477K1 (en) * 1982-07-16 1984-01-26
JPS632524B2 (en) * 1982-08-04 1988-01-19 Lion Corp
US4585650A (en) * 1982-10-04 1986-04-29 White Laboratories, Inc. Skin lubricating cosmetic composition
JPS6323167B2 (en) * 1982-11-12 1988-05-16 Lion Corp
JPS59134717A (en) * 1983-01-20 1984-08-02 Nitto Electric Ind Co Ltd Tacky plaster base
JPH039884B2 (en) * 1983-04-20 1991-02-12 Sunstar Kk
EP0126348A2 (en) * 1983-05-19 1984-11-28 Kyoto Pharmaceutical Industries, Ltd. Composition for rectal administration and method of promoting rectal drug absorption
JPS6347684B2 (en) * 1983-06-20 1988-09-26 Kao Soap Co
JPS60501604A (en) * 1983-06-21 1985-09-26
EP0187433B1 (en) * 1983-08-01 1990-12-27 Teijin Limited Powdery pharmaceutical composition suitable for application to mucosa of oral or nasal cavity
JPS60166617A (en) * 1984-02-08 1985-08-29 Yamanouchi Pharmaceut Co Ltd Nicardipine hydrochloride agent for external use
US4637930A (en) * 1984-02-08 1987-01-20 Yamanouchi Pharmaceutical Co, Ltd. Transdermal formulation of nicardipine hydrochloride
JPS6127908A (en) * 1984-07-17 1986-02-07 Kao Corp Preventive for chapping
JPS6237640B2 (en) * 1984-10-16 1987-08-13 Abe Yukagaku Kenkyusho Jugen
JPH0236572B2 (en) * 1984-11-13 1990-08-17 Hokuriku Pharmaceutical Suteroidoo177monoesuteruganjukuriimuzai
JPS61267528A (en) * 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd Transnasal calcitonin agent containing absorbefacient
JPH0380123B2 (en) * 1985-02-06 1991-12-24 Shiseido Co Ltd
US4608370A (en) * 1985-03-04 1986-08-26 Aronsohn Richard B Skin formulation
JPH0519526B2 (en) * 1985-03-11 1993-03-17 Shiseido Co Ltd
JPH0533683B2 (en) * 1985-03-13 1993-05-20 Shiseido Co Ltd
JPH0358326B2 (en) * 1985-03-14 1991-09-05 Shiseido Co Ltd
JPH064529B2 (en) * 1985-03-20 1994-01-19 株式会社資生堂 External preparation for skin
JPH0372202B2 (en) * 1985-04-12 1991-11-18 Shiseido Co Ltd
JPS61289016A (en) * 1985-06-17 1986-12-19 Pola Chem Ind Inc Skin external agent
US4608730A (en) * 1985-07-05 1986-09-02 Viskase Corporation Disposable tension sleeve for a stuffing machine
JPH0437044B2 (en) * 1985-08-15 1992-06-18 Yakurigaku Chuo Kenkyusho Kk
DE3540175C2 (en) * 1985-11-13 1997-03-27 Merck Patent Gmbh Dithranolhaltige pharmaceutical preparation
JPH0747535B2 (en) * 1985-11-26 1995-05-24 日東電工株式会社 Anti-inflammatory analgesic patch
JPS62129212A (en) * 1985-11-29 1987-06-11 Pola Chem Ind Inc Cosmetic
FR2591105B1 (en) * 1985-12-11 1989-03-24 Moet Hennessy Rech A pharmaceutical composition, especially dermatological, or cosmetic, a basic hydrated lipidic lamellar phases or of liposomes containing a retinoid or a structural analogue of said retinoide such as carotenoid.
JPS62195316A (en) * 1986-02-20 1987-08-28 Kao Corp Dermatic drug
GB8606368D0 (en) * 1986-03-14 1986-04-23 Unilever Plc Skin treatment composition
US4929722A (en) * 1986-06-06 1990-05-29 Union Carbide Chemicals And Plastics Company Inc. Acid decrystallization of aminopolysaccharides and derivatives thereof
US5389677B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of treating wrinkles using glycalic acid
US5385938B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of using glycolic acid for treating wrinkles
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
CA1324077C (en) * 1986-12-23 1993-11-09 Scott Eugene J. Van Additives enhancing topical actions of therapeutic agents
US4983382A (en) * 1987-01-27 1991-01-08 Avon Products, Inc. Cosmetic preparation incorporating stabilized ascorbic acid
US5021451A (en) * 1988-11-14 1991-06-04 Hoffman-La Roche Inc. Method for inhibiting hyperproliferative diseases
US5153230A (en) * 1989-10-06 1992-10-06 Perfective Cosmetics, Inc. Topical skin cream composition
GB9003201D0 (en) * 1990-02-13 1990-04-11 Unilever Plc Cosmetic composition
US5093109A (en) * 1990-04-04 1992-03-03 Chanel, Inc. Cosmetic composition

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7404967B2 (en) * 1994-12-21 2008-07-29 Cosmederm, Inc. Topical product formulations containing strontium for reducing skin irritation
US20030124202A1 (en) * 1994-12-21 2003-07-03 Hahn Gary S. Formulations and methods for reducing skin irritation
US8449923B2 (en) 1994-12-21 2013-05-28 Cosmederm Bioscience, Inc. Methods for inhibiting sensory nerves by topically administering strontium-containing compositions to keratinized skin
US20020098210A1 (en) * 1997-06-23 2002-07-25 Hahn Gary S. Formulations and methods for reducing skin irritation
US6949249B2 (en) 2000-05-08 2005-09-27 Pfizer Inc. Skin protectant spray compositions
US20060200174A1 (en) * 2001-05-08 2006-09-07 Stough Dowling B Wart removal method and device
US9456970B2 (en) 2001-05-31 2016-10-04 Upsher-Smith Laboratories, Inc. Dermatological compositions and methods
US8013017B2 (en) 2001-05-31 2011-09-06 Upsher-Smith Laboratories, Inc. Dermatological compositions and methods
US20110223621A1 (en) * 2001-10-05 2011-09-15 Curtis Keith Combinations for the treatment of immunoinflammatory disorders
EP1448205A4 (en) * 2001-10-05 2007-01-03 Combinatorx Inc Combinations for the treatment of immunoinflammatory disorders
EP1448205A2 (en) * 2001-10-05 2004-08-25 Combinatorx, Incorporated Combinations for the treatment of immunoinflammatory disorders
US7253155B2 (en) 2001-10-05 2007-08-07 Combinatorx, Inc. Combinations for the treatment of immunoinflammatory disorders
US7915265B2 (en) 2001-10-05 2011-03-29 Zalicus Inc. Combinations for the treatment of immunoinflammatory disorders
EP2279742A3 (en) * 2001-10-05 2011-04-20 Zalicus Inc. Combinations for the treatment of immunoinflammatory disorders
US20070010502A1 (en) * 2003-10-15 2007-01-11 Combinatorx Inc. Methods and reagents for the treatment of immunoinflammatory disorders
US8080553B2 (en) 2003-10-15 2011-12-20 Zalicus Inc. Methods and reagents for the treatment of immunoinflammatory disorders
US20050095261A1 (en) * 2003-11-03 2005-05-05 Popp Karl F. Antimicrobial topical compositions for treatment of rosacea
US20050095215A1 (en) * 2003-11-03 2005-05-05 Popp Karl F. Antimicrobial shampoo compositions
US20090030060A1 (en) * 2004-10-29 2009-01-29 Tolmar, Inc. Intravaginal treatment of vaginal infections with metronidazole compositions
US20070231358A1 (en) * 2004-10-29 2007-10-04 Tolmar, Inc. Intravaginal treatment of vaginal infections with metronidazole compositions
US20060093675A1 (en) * 2004-10-29 2006-05-04 Mathew Ebmeier Intravaginal treatment of vaginal infections with metronidazole compositions
US20070071705A1 (en) * 2005-09-29 2007-03-29 De Oliveira Monica A M Topical anti-microbial compositions
US20080003213A1 (en) * 2006-05-22 2008-01-03 Jan Lessem Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein, interleukin-6, or interferon-gamma levels
US20090075955A1 (en) * 2007-09-19 2009-03-19 Combinatorx, Inc. Therapeutic regimens for the treatment of immunoinflammatory disorders
US20110189293A1 (en) * 2007-12-17 2011-08-04 CombinatoRx, Incoporated Therapeutic regimens for the treatment of immunoinflammatory disorders
US20100261792A1 (en) * 2008-11-20 2010-10-14 Chata Biosystems, Inc. Alpha-Keto Alkylperacids and Methods For Producing and Using the Same
US8445717B2 (en) 2008-11-20 2013-05-21 Chd Bioscience, Inc. α-Keto alkylperacids and methods for producing and using the same
US20100125104A1 (en) * 2008-11-20 2010-05-20 Chata Biosystems, Inc. Alpha-Keto Peracids and Methods For Producing and Using the Same
US9012681B2 (en) 2008-11-20 2015-04-21 Chd Bioscience, Inc. α-keto peracids and methods for producing and using the same
US9018412B2 (en) 2008-11-20 2015-04-28 Chd Bioscience, Inc. α-keto alkylperacids and methods for producing and using the same
US8426634B2 (en) 2008-11-20 2013-04-23 Chd Bioscience, Inc. α-keto peracids and methods for producing and using the same
US9844219B2 (en) 2008-11-20 2017-12-19 Chd Bioscience, Inc. Alpha-keto peracids and methods for producing and using the same
US9468622B2 (en) 2008-11-20 2016-10-18 Chd Bioscience, Inc. α-keto peracids and methods for producing and using the same
US9044527B2 (en) 2011-02-17 2015-06-02 Chd Bioscience, Inc. Wound care products with peracid compositions
US9877483B2 (en) 2012-10-18 2018-01-30 Armis Biopharma, Inc. Compositions comprising peroxyacid and methods for producing and using the same
US9283202B2 (en) 2012-10-18 2016-03-15 Chd Bioscience, Inc. Stable peracid-containing compositions
US9545368B2 (en) 2013-08-09 2017-01-17 The Chemours Company Fc, Llc Skin care compositions having cyclic diesters and methods thereof
KR101602468B1 (en) 2014-01-17 2016-03-10 주식회사 엘지생활건강 Cosmetic or pharmaceutical composition for promoting hair growth containing Hydroxydecanoic acid
KR20150085970A (en) * 2014-01-17 2015-07-27 주식회사 엘지생활건강 Cosmetic or pharmaceutical composition for promoting hair growth containing Hydroxydecanoic acid
US9578879B1 (en) 2014-02-07 2017-02-28 Gojo Industries, Inc. Compositions and methods having improved efficacy against spores and other organisms

Also Published As

Publication number Publication date Type
DE3751361T2 (en) 1995-12-14 grant
CA1324077C (en) 1993-11-09 grant
EP0599819A3 (en) 1994-07-27 application
DE3752045T2 (en) 1997-11-13 grant
JPS63166837A (en) 1988-07-11 application
DE3751361D1 (en) 1995-07-27 grant
EP0599819B1 (en) 1997-04-02 grant
US5665776A (en) 1997-09-09 grant
US20030017130A1 (en) 2003-01-23 application
JP2533339B2 (en) 1996-09-11 grant
DE3752045D1 (en) 1997-05-07 grant
EP0599819A2 (en) 1994-06-01 application
EP0273202A2 (en) 1988-07-06 application
ES2103506T3 (en) 1997-09-16 grant
EP0273202B1 (en) 1995-06-21 grant
EP0273202A3 (en) 1990-06-06 application
ES2074978T3 (en) 1995-10-01 grant
EP0770399A2 (en) 1997-05-02 application

Similar Documents

Publication Publication Date Title
US6149924A (en) Composition for enhancing lipid production, barrier function, hydrogen peroxide neutralization, and moisturization of the skin
US5652266A (en) Cosmetic or dermatological compositions
US6673374B2 (en) Pharmaceutical compositions and methods for managing skin conditions
US5409693A (en) Method for treating and preventing sunburn and sunburn damage to the skin
US5441740A (en) Cosmetic composition containing alpha hydroxyacids, salicyclic acid, and enzyme mixture of bromelain and papain
US20030007939A1 (en) Pharmaceutical compositions and methods for managing dermatological conditions
US5420106A (en) Method and composition having enhanced alpha-hydroxy acid skin permeation and retention
US3879537A (en) Treatment of ichthyosiform dermatoses
US20020039591A1 (en) Topical applications for skin treatment
US20030229141A1 (en) N-acetyl cysteine and its topical use
US5885595A (en) Cosmetic composition with a retinol fatty acid ester
US5574063A (en) Method and compositions for topical application of ascorbic acid fatty acid esters for treatment and/or prevention of skin damage
US5643949A (en) Phenyl alpha acyloxyalkanoic acids, derivatives and their therapeutic use
US5621008A (en) N-acyl-ethylene-triacetic acids
US5093360A (en) Retinal, derivatives and their therapeutic use
US5723109A (en) Use of salicyclic acid derivatives for depigmenting the skin
US6429231B1 (en) Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use
US5516793A (en) Use of ascorbic acid to reduce irritation of topically applied active ingredients
US5788972A (en) Product for topical application containing a lipase and an active ingredient precursor
US5885593A (en) Skin care composition including cyclodextrin materials and method for treating skin therewith
US6120779A (en) Use of partial and complete salts of choline and carboxylic acids for the treatment of skin disorders
US4960772A (en) Benzoyl peroxide and quaternary ammonium based pharmaceutical and cosmetic compositions
US6824786B2 (en) Compositions comprising phenyl-glycine derivatives
US20050129787A1 (en) Pharmaceutical compositions and methods for managing connective tissue ailments
US6271246B1 (en) Pharmaceutical compositions for managing scalp conditions

Legal Events

Date Code Title Description
AS Assignment

Owner name: TRISTRATA TECHNOLOGY, INCORPORATED, DELAWARE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TRISTRATA, INCORPORATED;REEL/FRAME:012238/0090

Effective date: 20010927

AS Assignment

Owner name: TRISTRATA, INCORPORATED, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YU, RUEY J.;SCOTT, EUGENE J. VAN;REEL/FRAME:012238/0419

Effective date: 20010927